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Abstract 
Intracranial aneurysm (IA) is a vascular condition characterized as a saccular 
dilatation of the cerebral artery wall. The purpose of this study was to identify genetic 
variants that cause susceptibility to IA in two multiplex families from Newfoundland and 
Labrador. Whole exome sequencing was completed for 12 affected individuals from 
families R1352 and R1256. A filtering strategy was then implemented to identify and 
prioritize rare variants that were shared by multiple affected family members. In family 
R1352, two variants were identified as top candidates: C4orf6 c.1A>G, and GIGYF2 
c.3494A>G. Both were present in 6/7 exomes from the family, and passed all filtering 
steps. In family R1256, SPDYE4 c.103C>T was identified as a variant of interest, as it 
segregated in 10/11 affected individuals. Though each variant exhibited incomplete 
segregation, all three were absent from 100 local population controls. The absence of a 
definitive candidate variant in the exome suggests that further study is necessary to gain 
better understanding of the genetic etiology of this disease.    
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 1 
1. Introduction 
1.1 Intracranial Aneurysm 
 1.1.1 Aneurysm, Subarachnoid Hemorrhage, and Stroke     
An intracranial aneurysm (IA) is a dilatation or balloon-like growth of the wall of 
a cerebral artery. These arterial lesions can vary in shape and size, and have the potential 
to expand over time. Saccular or berry-shaped IA is the most common form and will be 
discussed throughout this thesis (Tromp, Weinsheimer, Ronkainen, & Kuivaniemi, 2014). 
Saccular aneurysms often occur at bifurcations of arteries at the base of the brain, and as 
a result, IA development is concentrated in the area of the cerebral vasculature known as 
the Circle of Willis (Figure 1) where junctions are prevalent (Williams & Brown, 2013). 
IA location varies across affected individuals, though usual target sites include the 
internal carotid artery (ICA), middle cerebral artery (MCA), anterior and posterior 
communicating arteries (ACOMM and PCOMM), anterior and posterior cerebral arteries 
(ACA and PCA), posterior inferior cerebellar artery (PICA), ophthalmic artery, vertebral 
artery, and the tip of the basilar artery (Brown & Broderick, 2014).  
 IAs can be difficult to diagnose, as their formation can be asymptomatic. 
However, the weakened vessel walls of IAs have a high potential to rupture, resulting in 
bleeding in the subarachnoid space (Frosen et al., 2012). Uncontrolled bleeding in this 
space between the brain and skull can cause a type of hemorrhagic stroke called 
subarachnoid hemorrhage (SAH). The main symptom of SAH is a sudden severe 
headache that is often followed by nausea, vomiting, and neck stiffness, and can rapidly  
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Figure 1.  Common sites for saccular intracranial aneurysms. Reprinted from 
Williams & Brown (2013) with copyright permission. 
 
The Circle of Willis is a known site of aneurysm development. Several major arteries interact and 
communicate at this juncture, to ensure proper blood supply throughout the brain. 
 
 
 
 
 
 3 
progress to widespread neurological and physical effects (de Oliveira Manoel et al., 
2015). 
Hemorrhagic stroke, which encompasses both intracerebral hemorrhage and SAH, 
contributes significantly more to global stroke burden than ischemic strokes caused by 
obstructed cerebral vessels (Krishnamurthi et al., 2014). Of the 5.3 million cases of 
hemorrhagic stroke that occurred worldwide in 2010, 3.0 million resulted in death. The 
majority of stroke cases occur in low to middle income countries, which may be 
attributed to differences in diagnostic capabilities and access to treatment (Krishnamurthi 
et al., 2014). However, stroke is still the third leading cause of death in North America, 
and is responsible for 14,000 deaths in Canada every year (Mukherjee & Patil, 2011; 
Statistics Canada, 2011). IA rupture is responsible for about 85% of SAH incidences, and 
SAH itself has a high mortality rate of approximately 50% (Starke, Chalouhi, Ding, & 
Hasan, 2015). Due to the devastating nature of IA and the impact of stroke on the global 
population, the study of this condition is of great importance. The identification of risk 
factors is a step toward reducing the burden of IA and its complications.   
 1.1.2 Risk Factors for IA Development and Rupture 
Several factors play a role in the formation of IA, and consequently, the severity 
and outcome after diagnosis. Unruptured IA has a prevalence of 3.2% in the general 
population, as estimated by a meta-analysis of 68 studies in 83 study populations, with an 
equal proportion of men and women, a mean age of 50, and an absence of comorbidity 
(Vlak, Algra, Brandenburg, & Rinkel, 2011). However, individuals between the ages of 
40 and 60 have the highest risk for IA development (International Study of Unruptured 
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Intracranial Aneurysms Investigators, 1998). IA is very rare in children, as these lesions 
are typically acquired later in life (Frosen, 2014). Females are also affected more often 
than males. Vlak et al. (2011) determined that the prevalence of unruptured IA in women 
was 6%. In their analysis, the female/male prevalence ratio increased from 1.61 to 2.2 
when they considered only individuals over the age of 50. As a result, some studies have 
suggested that there could be a physiological determinant that is influencing this sex 
difference, which increases with age. It has been hypothesized that a decrease in estrogen 
levels and cerebrovascular estrogen receptor density in post-menopausal women might 
result in increased IA risk, due to the role of estrogen in inflammatory-related processes 
(Harrod, Batjer, & Bendok, 2006).   
Though some factors are beyond our control, many modifiable risk factors also 
exist. Smoking, hypertension, and excessive alcohol use are all known to increase the risk 
of IA development as well as progression to rupture (Hussain, Duffis, Gandhi, & 
Prestigiacomo, 2013). Therefore, lifestyle changes are an integral part of aneurysm 
prevention and management. Finally, genetic predisposition has been identified as a risk 
factor for both IA development and rupture. This is suggested based on the fact that, 
while IA can occur sporadically, it can also be concentrated in families. Research has 
shown that the first-degree relatives of IA patients are at a 4 time greater risk of 
developing the disease (Hussain et al., 2013). Familial aneurysms have an earlier age of 
onset, on average, and pose a greater rupture risk (Broderick et al., 2009). Over the past 
20 years, the genetic contribution to both sporadic and familial IA has been explored 
using various research techniques. Despite these efforts, the genetic etiology of this 
disease is not well understood, and further research is necessary to explain IA at the 
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molecular level. Evidence regarding the genetic etiology of IA will be explored in detail 
in section 1.2.  
 1.1.3 Screening and Treatment for IA  
 If an individual is at high risk for IA, or has a family history of the disease, a 
physician can suggest screening by magnetic resonance angiography (MRA) or computed 
tomography angiography (CTA) to establish a diagnosis. Both methods have a high 
degree of accuracy for aneurysms larger than 3 mm (Williams & Brown, 2013). 
Unfortunately, approximately 50% of IA cases are diagnosed only after SAH has 
occurred (Brown & Broderick, 2014). More than 30 years ago, Fox (1982) demonstrated 
the impact of screening when family history is known, in a short case report. He 
described a family with multiple cases of IA, with two siblings who would not agree to 
undergo elective screening for undiagnosed IA. A couple of years after the original study 
was published, one of these siblings suffered a severe SAH, and died shortly thereafter 
from complications.   
Following confirmation of unruptured IA, or an SAH episode, one of several 
treatment options may be considered. Surgical clipping and endovascular coiling are the 
two most common interventions, though each carries significant risk (Figure 2). One of 
these strategies could be employed to prevent rupture, or to reduce the chance of re-
bleeding and the accompanying neurological complications of SAH (de Oliveira Manoel 
et al., 2015).  
Surgical clipping is an invasive procedure that involves a craniotomy, followed by 
the placement of a metal clip around the aneurysmal neck. This action separates the IA  
 6 
 
 
 
Figure 2. Types of unruptured intracranial aneurysm interventions: (A) aneurysm 
clipping, (B) endovascular coiling, (C) endovascular coiling with stent assistance. 
Reprinted from Williams & Brown (2013) with copyright permission. 
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from the rest of the main artery, to prevent the entry of blood (Williams & Brown, 2013). 
In contrast, endovascular coiling is a common and relatively new treatment, which is less 
invasive than clipping. In this method, platinum coils are delivered into the aneurysm to 
isolate it from the affected artery (Williams & Brown, 2013). A stent may be used in 
conjunction with this procedure in some difficult cases, such as when the aneurysmal 
neck is wide.  A neurosurgeon must weigh the risks of IA complication with the risks of 
treatment, to decide the best course of action (Brown & Broderick, 2014). In addition to 
aneurysm size and location, the age of the patient, family history, and medical history 
must be considered. For example, an older patient with a small IA and other serious 
health issues may not be an ideal candidate for intervention. Alternatively, patients may 
be recommended for “conservative management”, where they are screened periodically 
to track the progression of the IA (Bederson et al., 2000).  
 1.1.4 Pathophysiology  
Several hypotheses have been presented regarding the pathophysiology of IA, but 
many questions still remain. The exact order of steps in the development and rupture of 
an IA is much debated, though most research points to a shared set of events. A study by 
Chalouhi et al. (2012) stated that the common pathway for intracranial aneurysm 
development consists of endothelial injury, inflammatory response, vascular smooth 
muscle cell modulation, extracellular matrix remodeling, and apoptosis, leading to the 
degradation of the artery wall.  
 Normally, cerebral arteries consist of three layers (Figure 3): the outer adventitia, 
the media, and the inner intima (Y. Wang et al., 2014). The hemodynamic stress of  
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 Figure 3. Intracranial arterial wall. Reprinted from Ruigrok, Rinkel & Wijmenga 
(2005) with copyright permission.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9 
turbulent blood flow at arterial junctures, in conjunction with modifiable and non-
modifiable IA risk factors, initiates a cascade of events that alters the structure of these 
layers. Experimental models of IA have shown that this stress causes the dysfunction of 
endothelial cells, which become elongated and experience a change in density. In 
addition to physical changes, signaling in the endothelium is altered (Chalouhi, Hoh, & 
Hasan, 2013). For example, Aoki et al. (2011) demonstrated that shear stress causes the  
activation of the prostaglandin E2/prostaglandin E receptor 2 (PGE2/EP2) pathway in                  
endothelial cells, which is involved in the promotion of inflammation. Modified 
endothelial cells also express monocyte chemoattractant protein-1 (MCP-1), which 
causes the recruitment of macrophages and additional leukocytes into the cerebral artery 
(Chalouhi et al., 2013).  
Another known feature of IA pathology is the phenotypic modulation of vascular 
smooth muscle cells (VSMCs). VSMCs are located in the media layer of the artery, and 
are normally involved in contraction and dilation (Chalouhi et al., 2013). During 
aneurysm development, VSMCs migrate to the intima, as a response to endothelial 
injury. These VSMCs respond by synthesizing collagen and thickening the wall, which is 
referred to as intimal hyperplasia and is a known response to vessel damage and wounds 
(Frosen, 2014). VSMCs in the intima become less compacted and weaker than their 
media counterparts, thus undergoing several functional changes to enter a pro-
inflammatory differentiated state. Intimal VSMCs stimulate the production of matrix 
metalloproteinases (MMPs), which are enzymes that degrade collagenous fibers and 
result in the loss of the extracellular matrix (Chalouhi et al., 2012). Ali et al. (2013) used 
western blot analysis to demonstrate that MMP-3 and MMP-9 are expressed in rat 
 10 
cerebral VSMCs that have been treated with tumour necrosis factor alpha (TNF-α), a pro-
inflammatory cytokine. TNF-α is part of the immune system’s response to stress, and has 
increased expression in the wall of IAs. As well, Ali et al. (2013) showed that the smooth 
muscle cell proteins SM-MHC (smooth muscle myosin heavy chain), SM-α-actin, and 
SM-22-α had reduced expression in rat VSMCs following TNF-α treatment. A decrease 
in the expression of these contractile proteins would provide evidence for the role of 
TNF-α in the modulation of VSMCs from a muscle contraction role to a pro-
inflammatory role in the body.  
 As demonstrated above, the role of inflammation is predicted to be integral to IA 
pathogenesis. Both VSMC and endothelium modification is involved in the production of 
an inflammatory response and the loss of essential layers of the arterial wall. Like intimal 
VSMCs, macrophages that have been recruited to the site of vascular injury have been 
shown to produce MMPs, cytokines and other inflammatory agents (Figure 4). For 
example, the cytokine interleukin-1 beta (IL1β) has been detected following induced IA 
formation in mice (Moriwaki et al., 2006). Specifically, IL1β activity was involved in the 
promotion of VSMC apoptosis in this model. In addition to the death of VSMCs and 
consequently the degradation of the ECM, inflammatory mediators also disrupt the 
internal elastic lamina. The internal elastic lamina (IEL) is located between the intima 
and media layers, and helps to maintain elasticity in the artery and inhibit over-expansion 
of the wall (Frosen, 2014). However, IAs have a characteristic lack of IEL, which 
increases the workload of collagen fibers. Strain on the remaining collagen fibers in 
conjunction with VSMC apoptosis results in a loss of collagen and overall thinning of the  
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Figure 4. Inflammatory reaction associated with intracranial aneurysm formation 
and rupture. Reprinted from Chalouhi et al. (2012) with copyright permission. 
 
This hypothesized pathway shows that the action of various inflammatory agents triggers the 
progression from weakened artery wall to aneurysm formation. The highlighted processes are 
influenced by environmental and genetic risk factors, demonstrating the multifactorial nature of 
IA. 
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media layer (Chalouhi et al., 2012). Overall, it is clear that a stimulated loss of structural 
capacity of the artery wall is key to the development of IA.  
 Following initial IA formation, these lesions often continue to grow or expand 
with the stress of blood flow and distension of the artery wall (Frosen, 2014). Frosen et 
al. (2012) succinctly stated that aneurysm rupture occurs “when blood pressure-induced 
tension of the wall exceeds it strength”. An ongoing active inflammatory response may 
also contribute to the eventual collapse of an IA (Chalouhi et al., 2013). Starke et 
al.(2015) recently suggested that aspirin and other anti-inflammatory medications should 
be explored as treatments to prevent aneurysm rupture. Better understanding of the exact 
biological processes that lead to IA formation, expansion and progression to rupture 
could lead to improved treatment, management, and even prevention. This understanding 
may come from the identification of genes, and consequently proteins, that are underlying 
the pathogenesis of this disease.   
 
1.2 The Genetic Contribution to IA  
 1.2.1 Preliminary Evidence 
 It is widely acknowledged that there is a genetic component to the development of 
IA. One significant piece of evidence is the association of IA development with heritable 
connective tissue disorders that have a vascular component, including Marfan syndrome, 
type IV Ehlers-Danlos syndrome, and autosomal dominant polycystic kidney disease 
(ADPKD) (Schievink, Michels, & Piepgras, 1994). The genes involved in the inheritance 
of these disorders are well described (Table 1). Most notably, ADPKD is caused by 
mutations in PKD1 and PKD2, which encode the extracellular matrix proteins  
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Table 1. Heritable connective tissue disorders that have been associated with IA, 
and related genetic risk factors.  
 
 
Syndrome  Causative Gene(s)  Corresponding Proteins 
Autosomal dominant polycystic 
kidney disease 
PKD1, PKD2 Polycystin-1, Polycystin-2 
Marfan syndrome FBN1  Fibrillin-1  
Neurofibromatosis type I NF1 Neurofibromin 
Ehlers-Danlos syndrome type IV COL3A1  Collagen alpha 1 (III) chain 
Pseudoxanthoma elasticum ABCC6 Multidrug resistance-
associated protein 6 
Supravalvular aortic stenosis ELN  Elastin 
Multiple endocrine neoplasia type I  MEN1 Menin 
Hereditary hemorrhagic 
telangiectasia  
SMAD4, ENG, ACVRL1 Mothers against 
decapentaplegic homolog 4, 
Endoglin, Serine/threonine-
protein kinase receptor R3 
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polycystin-1 and polycystin-2 respectively, and approximately 10% of ADPKD patients 
will develop IA (Chapman et al., 1992; Zhang & Claterbuck, 2008). IA is known as the 
symptom of ADPKD that contributes the most to disease-related mortality (Rossetti & 
Harris, 2013). Other genetic syndromes have also been associated with an elevated risk of 
cerebral aneurysm, including Moyamoya disease, sickle-cell disease, and fibromuscular 
dysplasia (Brown & Broderick, 2014).  
 Additionally, IA can occur in patients afflicted by other types of aneurysms. 
Aneurysm growth is not limited to the cerebral vasculature, and lesions on the thoracic 
and abdominal regions of the aorta can occur as isolated or familial incidences. Regalado 
et al. (2011) described multiple families with autosomal dominant inheritance of thoracic 
aortic aneurysms and dissections (TAAD), where some affected relatives also had IA 
and/or abdominal aortic aneurysms (AAA). Through the study of five of these families, 
four rare mutations in the SMAD3 gene were identified.  They were able to conclude that 
SMAD3 mutations can explain 2% of familial TAAD cases, and more significantly, that 
there may be a common genetic mechanism that connects all arterial aneurysms 
(Regalado et al., 2011). 
 However, to date, no causative genes for non-syndromic IA have been defined. 
Review of the published literature has revealed an abundance of research aiming to 
uncover the gene or genes involved in IA development and progression. Functional 
studies have yet to show a connection between identified genetic variants and the 
manifestation of IA. Evidence including the co-occurrence of IA with other genetic 
syndromes and aneurysms, the observation of IA clustering in families, and the increased  
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risk associated with a family history of the disease have all catalyzed further 
investigation.   
 1.2.2 Family-Based Studies 
Twin studies are a well-known and highly useful approach for exploring the 
influence of genetics on disease risk. Leung et al. (2011) completed a review of the 
literature, and found that only 15 twin pairs with IA had been described before 2011. 
Seven of these pairs had IAs in the same location in the vasculature. On average, the time 
between diagnosis of the first twin, and development of IA in the second twin was 2.4 
years. Leung et al. (2011) also reported on a newly identified monozygotic twin pair with 
IA, where the first twin was diagnosed with an aneurysm of the left ICA at the age of 57. 
The other twin underwent screening, which resulted in the diagnosis of a right ICA 
aneurysm. Interestingly, these twins demonstrated IA at “mirror sites”, which is another 
feature seen in 3/15 of the pairs previously described. In a recent article by Mackey et al. 
(2015), additional twin-pairs were identified from the Familial Intracranial Aneurysm 
Study cohort. These participants are part of a large-scale international study of familial 
IA (Broderick et al., 2005). Of the 11 monozygotic twin pairs enrolled in their study, 8 
demonstrated IA location concordance. The same phenomenon was only observed in 1 of 
5 dizygotic twin pairs, providing evidence for a genetic contribution to IA location and 
incidence (Mackey et al., 2015).  
Along with twin-pairs affected by IA, many multiplex families have been 
described. These studies have provided integral insight into the mode of inheritance of 
familial IA. In particular, a study conducted by Wills et al. (2003) describes 346 Finnish 
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families and their predicted inheritance patterns. Each family had at least 2 affected 
members, while 14 of these 346 families had particularly strong family history, with 6 or 
more affected members. Wills et al. (2003) reported that 57.2% of the families had a 
pattern of inheritance that was characteristic of an autosomal recessive mode of 
inheritance, and 36.4% were consistent with an autosomal dominant mode. They 
indicated that 5.5% of the pedigrees were consistent with an autosomal dominant 
incompletely penetrant mode, and the remaining 0.9% of families did not fit any 
Mendelian pattern of inheritance. It was emphasized that across their cohort there was 
father-to-son, father-to-daughter, mother-to-son, and mother-to-daughter transmission of 
IA, providing evidence for autosomal inheritance in this disease (Wills et al., 2003). In 
addition to showing the degree to which IA aggregates in families, this large-scale study 
showed that familial IA might follow multiple inheritance patterns.  
In order to further explore the genetic contribution to IA in families, many 
researchers have turned to DNA linkage analysis. In a recent review article, Tromp et al. 
(2014) highlighted six chromosomal loci that were identified in at least two independent 
linkage studies of IA, and had significant logarithm of odds (LOD) scores above 2.0. 
These regions are 1p34-36, 4q32, 7q11, 19q13, and Xp22. A detailed description of the 
respective publications and study designs is shown in Table 2.  
 Ruigrok et al. (2008) were able to replicate two of these previously reported loci, 
1p36.11-p36.13 and Xp22, in a single consanguineous family from the Netherlands. First, 
they used a linkage panel of 5,861 single nucleotide polymorphisms (SNPs) to genotype 
17 family members. Twenty-four additional microsatellite markers were then genotyped 
corresponding to regions that were of particular interest. Using the GENEHUNTER  
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Table 2. Genomic regions described in two or more previous linkage analyses of 
familial IA. 
 
Locus Publications Cohort Study Design 
1p34-36 Nahed et al.(2005) 1 North American family (AD) Parametric 
Ruigrok et al. (2008) 1 Dutch family  Non-parametric 
4q32 Foroud et al. (2008) 192 International families Non-parametric 
Foroud et al. (2009) 333 International families Parametric 
7q11 Onda et al. (2001) 85 Japanese families Sibling pairs  
Farnham et al. (2004) 13 North American families 
(AR) 
Parametric 
19q13 Olson et al. (2002) 85 Finnish families Sibling pairs  
van der Voet et al. (2004) 333 Finnish families  Sibling pairs  
 Yamada et al. (2004) 29 Japanese families Non-parametric  
 Mineharu et al. (2007) 9 Japanese families (AD) Parametric  
Xp22 Olson et al. (2002) 85 Finnish families Sibling pairs  
Yamada et al. (2004) 29 Japanese families Non-parametric 
 Ruigrok et al. (2008) 1 Dutch family  Non-parametric  
 
Abbreviations: AD = autosomal dominant, AR = autosomal recessive  
 
 
 
 
 
 
 
 
 
 
 18 
software, they selected a nonparametric or model-free approach, as the inheritance 
pattern for this family was unclear. Only known affected family members were included 
in this analysis. This software produces statistical estimates in the form of nonparametric 
linkage (NPL) scores, with scores above 3.18 being suggestive of linkage, and scores 
above 4.08 indicating significant linkage. For a series of markers at the 1p36 locus, there 
was a maximum NPL score of 3.18. For Xp22, there was a maximum NPL score of 4.54. 
It is possible that one or both of these linked regions could be of importance in familial 
IA. This study is of interest, as these results could also indicate that IA is digenic in this 
kindred.   
Similarly, Verlaan et al. (2006) used linkage analysis to identify a susceptibility 
locus for IA in a large French-Canadian family. The French-Canadian population from 
Quebec is known to exhibit founder effects, making haplotype analysis a useful method 
for investigating IA in this family. A total of 531 microsatellite markers were genotyped 
in nine affected and three unaffected family members. Based on the disease segregation 
in this pedigree, a parametric, affecteds-only approach was taken by the research team, 
assuming an autosomal dominant mode of inheritance. A locus on chromosome 5p had 
the strongest evidence for linkage, and fine mapping revealed a common disease 
haplotype between 5p15.2-14.3 that segregated with affected family members. The 
authors also mention that there are two known individuals in the family who are non-
penetrant for IA, and have the disease haplotype. Most of the affected family members 
are known smokers, whereas these two non-penetrant individuals are non-smokers. 
Therefore, it is possible that the inheritance of a disease locus alone may not be sufficient 
to result in IA manifestation in this family. However, as IA is known to be a late-onset 
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disease, the non-penetrant individuals could still develop IA later in life. Follow-up 
diagnostic testing of these individuals over time could provide answers regarding the 
relevance of this shared haplotype.  
One of the main challenges following linkage analysis is the identification of a 
specific gene or variant of interest, given a linked region. This issue of fine-mapping is 
exasperated by the fact that familial IA may have a high degree of genetic heterogeneity, 
and genomic regions identified through linkage analysis may be specific to certain 
families. Verlaan et al. (2006) identified two possible candidate genes in the 5p15.2-14.3 
region, CTNND2 and TRIO, both of which are involved in cell modeling. These are only 
two of 25 known genes in this region, and further in-depth study of these genes would be 
necessary to connect them to IA susceptibility.   
 1.2.3 Candidate Gene Studies 
Linkage analyses have led to the identification of several candidate genes for IA 
within linked genomic regions. These genes are generally selected for their functional 
relevance. For example, the elastin (ELN) gene has been identified as a candidate gene, 
for its proximity to the 7q11 linked region and the contribution of its protein product to 
the structure and elasticity of vessel walls (Tromp et al., 2014). Candidate gene study 
designs involve the selection of common polymorphisms found in or near a gene of 
functional interest. These polymorphisms are typically genotyped in sporadic IA cases to 
determine statistical association with disease occurrence, compared to genotyped controls 
(Tromp et al., 2014).  
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Krischek et al.  (2010) completed one such study, by focusing their attention on 
the JDP2 gene and its potential role in IA. They had previously identified the 14q22 
locus as a target for further exploration, through linkage analysis of affected sibling pairs 
from Japan (Onda et al., 2001). Initial genotyping of 100 SNPs located up and 
downstream from 14q22 was completed for 148 Japanese sporadic IA cases and 190 
controls, and statistical association was detected near the JDP2 gene (Krischek et al., 
2010). After genotyping more individuals (403 cases and 412 controls), a single SNP in 
the intronic region of JDP2 was associated with IA, with an odds ratio of 1.44. Ten SNPs 
in the JDP2 gene were then genotyped in Japanese, Korean, and Dutch case-control 
cohorts. A total of three SNPs were associated with IA in the Japanese cohort, with P-
values reaching significance (P < 0.05).  One of these intronic SNPs was also associated 
with IA in the Korean patient cohort (Krischek et al., 2010). They explained the 
relevance of this candidate by describing the jun dimerization 2 (JDP2) protein as a 
repressor of transcription activator protein 1 (AP-1). The AP-1 protein initiates apoptosis 
and, in the absence of a repressor, could cause vascular remodeling via cell death 
(Krischek et al., 2010).  
 In order to identify strongly associated SNPs, Alg et al. (2013) completed a meta-
analysis of IA candidate gene and genome-wide (discussed in section 1.2.4) association 
studies, enabling them to evaluate the accuracy of previously reported findings. If a SNP 
was associated with IA in more than study, a fixed-effect statistical model was used to 
pool odds ratios. They determined that eight SNPs, each found in at least two candidate 
gene studies, were significantly associated with IA with either a dominant, recessive or 
additive disease model. These SNPs were found in the genes SERPINA3 (rs4934), 
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COL1A2 (rs42524), COL3A1 (rs1800255), HSPG1 (rs3767137), CSPG2 (rs251124 and 
rs173686), ACE (rs4646994) and IL6 (rs1800796), all of which have integral functions in 
vascular biology and inflammation (Alg et al., 2013). Two variants in the CSPG2, or 
versican, gene were associated with IA in diverse cohorts, including Dutch and Japanese 
individuals with sporadic IA. The versican protein is a component of the extracellular 
matrix, and previous studies of AAA tissue have revealed decreased mRNA expression 
of versican, making it a gene of significant interest (Handley, Samiric, & Ilic, 2006; Alg 
et al., 2013) COL1A2 and COL3A1 are also clearly strong candidates, as the collagen 
proteins are a known structural component of the vascular adventitia (Ruigrok et al., 
2005). Unfortunately, to date, the relationship between IA candidate genes and their 
biological role in disease development has not been established. To uncover more loci 
that may be associated with IA, many researchers have turned to broader genome-wide 
investigations.  
 1.2.4 Genome-Wide Association Studies  
Genome-wide association studies (GWAS) have been instrumental to the 
evolving understanding of IA genetics, by providing a more comprehensive assessment 
of genomic variation. Several genomic regions have been associated with IA in more than 
one independent GWAS (Table 3), suggesting their potential roles in IA development, 
while others have not been replicated. The chromosomal region that has garnered the 
most attention for its association with IA is the 9p21 locus. Helgadottir et al. (2007) first 
reported an association between a common SNP at this locus, rs10757278, and 
myocardial infarction in a large sampling of the Icelandic population. This polymorphism  
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Table 3. Loci associated with IA in two or more GWAS.  
 
Locus Publications Study Population  Odds Ratio 
(OR) 
Candidate Genes 
in Region  
2q33.1 Bilguvar et al. (2008) Japan & Europe  OR=1.24 BOLL, PLCL1, 
ANKRD44 Kurki et al. (2014) Finland, Netherlands  OR=1.27 
4q31.23 Yasuno et al. (2011) Japan OR=1.22 EDNRA 
Low et al. (2012) Japan OR=1.25 
8q11.23-
12.1 
Bilguvar et al. (2008) Japan & Europe OR=1.36 SOX17 
Yasuno et al. (2010) Japan & Europe OR=1.28 
Foroud et al. (2012) Europe & USA OR=1.25 
9p21.3 Bilguvar et al. (2008) Japan & Europe OR=1.29 CDKN2A, 
CDKN2B Yasuno et al. (2010) Japan & Europe OR=1.32 
Low et al. (2012) Japan OR=1.21 
Foroud et al. (2012) Europe & USA OR=1.35 
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is adjacent to the CDKN2A and CDKN2B tumor suppressor genes, which have been 
classified for their role in apoptosis, proliferation, and other cellular functions (Magrane 
& Consortium, 2011). To investigate any further link between 9p21 and arterial disease, 
Helgadottir et al. (2008) genotyped rs10757278 in individuals affected by AAA, IA, or 
large artery atherosclerotic/cardiogenic stroke, and corresponding controls of European 
descent. They determined that rs10757278-G is a risk allele for both AAA and IA, in 
multiple populations. This association has been replicated in the four largest GWAS of 
IA to date (Bilguvar et al., 2008; Yasuno et al., 2010; Low et al., 2012; Foroud et al., 
2012). Each of these groups utilized large sporadic case-control cohorts in both the 
discovery and replication phases of their research, and were able to achieve results 
reaching genome-wide significance (Hussain et al., 2013). 
Bilguvar et al. (2008) performed the first large GWAS of IA utilizing both a 
discovery and replication cohort, which included more than 2,100 IA cases and 8,000 
control samples. During the discovery phase genotyping of Finnish and Dutch 
individuals, they found that SNPs at chromosomal regions 1q, 2q, 8q and 9p were 
associated with IA. Following replication in a Japanese cohort, eight SNPs were 
significantly associated with IA, at 2q33.1, 8q11.23 and 9p21.3, with P-values below 
1x10
-8
, the determined cut-off for genome-wide significance (Yasuno et al., 2010). To 
increase the power of this initial study, Yasuno et al. (2010) used the same Illumina 
platform to genotype 832,000 SNPs in two additional case cohorts and five control 
cohorts from Europe. A second Japanese replication cohort was also added. They used 
Bayesian statistics to calculate the posterior probability of association (PPA) for each 
SNP. They were able to confirm the associations at 8q11.23-q12.1 and 9p21.3, and 
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identify SNPs at three new loci that were associated with IA risk with PPA values greater 
than 0.5 (50%). These loci include 10q24.32, 13q13.1, and 18q11.2 (Figure 5). Given that 
these loci account for only a small percentage of overall IA risk, Yasuno et al. (2011) 
predicted that SNPs with a PPA value between 0.1-0.5 in the discovery cohort might also 
be significant following replication in the Japanese cohort. They genotyped 25 SNPs with 
a PPA in the 0.1-0.5 range in two Japanese case-control groups. One SNP in particular, 
rs6841581, was significantly associated with IA, with a final PPA of 0.986 following 
replication. This SNP is located at the 4q31.23 locus, which is close to the EDNRA gene. 
EDNRA encodes a G-protein coupled receptor for endothelins, including EDN1. EDN1, 
or endothelin-1, is involved in vasoconstriction and dilation of blood vessels, including 
most notably, cerebral arteries (Yasuno et al., 2011). The 4q31.23 locus grew in interest 
when an association was confirmed by Low et al. (2012) in their GWAS of the Japanese 
population.   
Low et al. (2012) performed a large-scale GWAS using a cohort of cases who had 
experienced SAH due to aneurysmal rupture. They successfully genotyped 565,149 SNPs 
in their discovery cohort of 1,383 SAH patients and 5,484 controls, and determined that 
several SNPs showed suggestive association with SAH. They genotyped 36 of these loci, 
and 7 that were previously associated with IA in other GWAS, in their replication cohort 
of 1,048 IA patients and 7,212 controls. One of these SNPs, rs6842241, was significantly 
associated with IA, with a P-value of 9.58x10
-9
. This SNP is located at 4q31.22, and also 
falls within the boundaries of the EDNRA gene. As stated previously, they also confirmed 
that rs10757278-G is a risk allele for IA development in the Japanese population (Low et 
al., 2012).  
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Figure 5. Functional candidate genes located at or near loci that are significantly 
associated with IA (P-value <1x10
-8
). Reprinted from Hussain et al. (2013) with 
copyright permission.  
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In their comprehensive study of the genetic etiology of IA, the Familial 
Intracranial Aneurysm (FIA) Study Investigators also completed a large-scale GWAS 
(Foroud et al., 2012). The GWAS described above involved the recruitment of patients 
with sporadic IA or SAH, without consideration of familial disease occurrence. One of 
the limitations of such a study design is that risk factors for sporadic IA may be separate 
from the factors contributing to familial IA development and rupture. To ameliorate this 
design, Foroud et al. (2012) created a study with two new discovery cohorts, with 
participants of European descent. Discovery Sample 1 included 388 cases from the FIA 
study, all with a family history of the disease. This sample also contained 397 control 
individuals. Discovery Sample 2 contained a mixture of 1,095 familial and sporadic IA 
cases, with 27% reporting a family history. This sample also included 1,286 controls. A 
SNP array was used for genotyping, and imputation was used to produce a common set of 
SNPs across both samples. Use of a logistic regression model showed that there were no 
risk variants unique to familial IA, as no associations reached genome-wide significance. 
This finding was interesting, as it suggests that the distinction between sporadic and 
familial IA cases might not influence experimental findings in GWAS. Multiple 
additional studies with sporadic and familial cohorts would be necessary to determine if 
family history has any impact on which loci are associated with IA.  
Meta-analysis of the results was performed across the two discovery samples, 
which led to the successful identification of a SNP reaching genome-wide significance. 
Foroud et al. (2012) confirmed a significant association between the SNP rs6475606 and 
IA in Caucasian individuals. This SNP is found in the CDKN2BAS gene region of 9p21. 
They also attempted to replicate the association between 8q11.23 and IA, which did not 
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achieve genome-wide significance. The 8q chromosome has been mentioned in multiple 
small and large-scale GWAS, and contains the candidate gene SOX17. Under-expression 
of SOX17 protein in a mouse model resulted in mutants with defective endothelial cell 
sprouting, which is a component of angiogenesis (Matsui et al., 2006). Many of the loci 
replicated throughout large-scale GWAS contain genes that are connected to vascular 
biology (Figure 5).    
In summary, linkage analyses and association studies have provided some 
potential functional candidates and common SNPs that are statistically associated with IA 
risk. A chromosomal map of these IA loci is provided in Figure 6. However, the 
translation of this knowledge has not yet been successful. No definitive genetic variant 
has been identified that causes IA. Therefore, the inclusion of new approaches that focus 
on rare and deleterious genetic variation in the genome should be explored. New 
innovative approaches to human genetics research could help determine what genetic 
factors are involved in the etiology of this disease.  
 1.2.5 Recent Strategies for IA Research   
In recent years, several new technologies have arisen for the study of genetic 
diseases. Foroud & FIA Study Investigators (2013) guided a new approach to IA research 
by using next generation sequencing to study the Familial Intracranial Aneurysm Study 
cohort. Specifically, they pursued whole exome sequencing (WES): a method used to 
capture and sequence the known protein-coding portion of the genome, which contains 
approximately 85% of the mutations described in Mendelian disorders (Ng et al., 2009; 
Z. Wang, Liu, Yang, & Gelernter, 2013). Exons and exon/intron boundaries only  
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Figure 6. Chromosomal map of IA loci identified through linkage, candidate gene 
and GWAS studies, and prioritized by Tromp et al. (2014). Used with permission 
under the Creative Commons license CC-BY-NC-ND 3.0 for the open access article 
by Tromp et al. (2014).   
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comprise about 1% of the human genome, but contain a vast amount of genetic variation 
with potential functional roles. A single exome of European-American descent contains 
an average of 20,000 coding variants, the majority of which are non-novel (Bamshad et 
al., 2011). Despite the abundance of known, common polymorphisms, an increasing large 
number of research groups have been able to use WES to describe rare, pathogenic 
variants in heritable diseases.   
Although it is difficult to identify causative variants in late-onset heritable 
disorders, pathogenic variants have been successfully elucidated through WES. Zimprich 
et al. (2011) employed WES to identify the causative variant for late-onset Parkinson’s 
disease in a large Austrian family, with autosomal dominant inheritance. This 
neurological disease affected sixteen members of the family, and seven participated in 
this study. The mean age of onset for the cohort was 53, and two affected second cousins 
were chosen for WES. Following filtering for rare heterozygous variants, a variant in the 
VPS35 gene, c.1858G>A, was prioritized. It was present in all seven affected individuals, 
and was later shown to segregate in two additional Austrian families with Parkinson’s 
disease (Zimprich et al., 2011).  This example demonstrates that WES-based studies have 
great potential where candidate gene sequencing has yielded negative results. WES is 
now widely used as a method to solve these cases, and explore diseases with genetic 
heterogeneity.  
Boileau et al. (2012) used WES to uncover the cause of familial TAAD in two 
unrelated families exhibiting autosomal dominant inheritance. Some family members 
without TAAD had a vascular phenotype in the form of IA and SAH. Mutations in the 
SMAD3 gene have been previously identified in individuals with similar phenotypes of 
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TAAD in five other families (Regalado et al., 2011). Additionally, TGFBR2 and FBN1 
are also known genes for thoracic aortic aneurysm (TAA) susceptibility (Faivre et al., 
2009; Loeys et al., 2006). However, in the Boileau et al. (2012) study, candidate gene 
sequencing did not yield any causative variants. Genome-wide linkage analysis revealed 
a significant locus at 1q41 in both families, which was then followed by WES to further 
explore missing heritability. Two affected individuals from an American family, 
TAA288, were exome sequenced, along with three affected and one unaffected individual 
from a French family, MS239. Following filtering of the exome data, both families had 
rare variants in the TGFB2 gene, which is located in the linked 1q41 region.  The 5-bp 
deletion (TAA288) and nonsense variant, p.C229* (MS239), were absent from control 
exomes, and were predicted to cause TAAD by haploinsufficiency of TGFB2.  
Given the success of WES in exploring adult-onset and vascular phenotypes, 
Foroud and colleagues used this technology to study familial IA (Foroud & FIA Study 
Investigators, 2013; Farlow et al., 2015). They sequenced the exomes of 45 individuals 
from seven families. The multiplex families published in this manuscript had a pedigree 
appearance of either autosomal dominant or recessive inheritance of IA. Through the use 
of the Genome Analysis Toolkit (GATK) Unified Genotyper software, a list of genetic 
variants was detected for each exome. A series of biological filters were then used to 
prioritize these variants, by factors such as minor allele frequency and gene function. The 
research group published a list of 68 rare variants in 68 genes that segregated with IA in 
at least one family (Farlow et al., 2015). Based on RNA expression data for 51 of these 
68 candidate genes, only the TMEM132B gene showed differential expression in IA 
tissue as compared to controls. In future analyses of the data, the authors plan to prioritize 
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the TMEM132B c.3050C>T (p.S1017L) variant, to determine its possible contribution to 
disease.  
A second WES-based study of IA was performed by Yan et al. (2015), and 
involved 42 individuals from 12 multiplex Japanese families. Following a systematic 
filtering approach, 78 single nucleotide variants were prioritized across this cohort. Only 
two of these variants were found in affected individuals from more than one family: 
c.578T>A (p.Y193F) in GPR63 and c.425C>T (p.R142H) in C10orf122. In addition, they 
completed an association study of 10 out of 78 variants, which were found in genes with 
gene ontology (GO) terms relating to angiogenesis. A variant in ADAMTS15, c.397G>C 
(p.E133Q), had the only significant association with IA following Bonferroni correction, 
with a P-value of 0.00013. Silencing of this gene in human umbilical venous endothelial 
cells caused increased endothelial cell migration, though further functional analysis at the 
cellular level is necessary (Yan et al., 2015). Both of these WES studies of IA have 
provided a starting point for delving into further exome-based research, though functional 
data will be required to determine if any of these variants are actually pathogenic and 
involved in IA development. These studies emphasize the use of advanced techniques in 
next generation sequencing to complement widely used genetics methodologies. 
Similarly, my research involves the application of WES to familial IA in Newfoundland 
and Labrador, where certain genetic diseases have been deeply phenotyped.      
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1.3 Studying IA in Newfoundland and Labrador  
 1.3.1 Heritable Disease Research in NL 
 The province of Newfoundland and Labrador has a unique population and history. 
The current population has largely grown from a group of initial immigrants, mainly of 
Irish and English descent, dating back to the mid-1700s (Rahman et al., 2003). The 
settlement of small outport communities around the province, combined with minimal 
immigration over time, has led to both geographic and genetic isolation (Rahman et al., 
2003). As a result, several rare monogenic diseases have an increased prevalence in this 
province, including Bardet-Biedl syndrome (Young et al., 1999) and arrhythmogenic 
right-ventricular cardiomyopathy (Merner et al., 2008). In addition, several complex 
diseases have a high prevalence in the NL population, including familial colorectal 
cancer (Green et al., 2007). Given the successful identification of mutations implicated in 
genetic disorders, the population of Newfoundland and Labrador has become attractive 
for genetics research (Rahman et al., 2003).  
 The recruitment process for IA families has been a long-term effort in this 
province. In our collaboration between the Discipline of Genetics at Memorial University 
and Eastern Health, 53 Newfoundland families with a strong family history of IA have 
been identified and enrolled in our study. Three families from Newfoundland and 
Labrador affected by familial IA were first described in a case study published by 
Maroun et al. (1986). The authors state that there is an increased prevalence of familial 
central nervous system disorders in the province. Six of seven SAH patients from the 
three families were diagnosed with ruptured IA, and the seventh individual was suspected 
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of having an IA. The average age of onset for these patients was relatively low, at 41.6 
years of age. A summary of the IA study cohort will be described in the Materials and 
Methods section of this thesis. Due to the previous success of heritable disease research 
in NL, and the genetic isolation of the population, this province is an ideal place to 
investigate the genetic etiology of IA.  
 1.3.2 Previous Work Completed  
Prior to the current study, several experiments were conducted in the Woods 
Laboratory using the IA cohort from Newfoundland and Labrador. In 2009, a study was 
published that explored the possibility of common genetic mechanisms between aortic 
aneurysms and IA (Santiago-Sim et al., 2009). Mutations in transforming growth factor 
beta (TGF-β) receptor genes are known to play a role in some familial cases of thoracic 
aortic aneurysm and dissection. To investigate the role of disrupted TGF-β signaling in 
IA risk, several TGF-β receptor genes, and genes related to this pathway, were sequenced 
in 44 familial IA patients, including TGFBR1, TGFBR2, TGFBR3, TGFB1, ACVR1, and 
ENG (Santiago-Sim et al., 2009). Novel variants in ENG (endoglin) and TGFBR3 
(transforming growth factor, beta receptor III) were identified in a subset of the cohort, 
but the pathogenicity of these variants could not be determined without further functional 
analysis (Santiago-Sim et al., 2009). Following the publication of this article, a research 
assistant in our laboratory completed Sanger sequencing of these two candidate genes in 
all probands from our IA families (53 in total) and in our cohort of sporadic individuals 
(N=33). However, no rare variants were identified in either of these genes. It was decided 
that sequencing of candidate genes might not be the best approach for our study of IA. As 
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we continue to investigate this disease, it is clear that the presence of genetic 
heterogeneity, and a general lack of knowledge surrounding the genetics of IA, may 
hinder the effectiveness of this method in the Newfoundland population.  
 In addition to candidate gene sequencing, SNP genotyping was outsourced for 
seven of our IA families using the Illumina Human610-Quad chip, followed by genome-
wide linkage analyses. The selected families (R1256, R1352, R1357, R1276, R1277, 
R1400 and R1888) have a particularly strong incidence of IA, and are highlighted in 
section 2.2. In total, 64 individuals were genotyped, for 620,901 SNPs. The final dataset 
contained 59 samples as five samples had a low call rate or were too distantly related for 
linkage considerations. The final number of SNPs was 574,441, as SNPs with a call rate 
below 99% were removed. Two-point and multipoint linkage analyses were performed, 
and both dominant and recessive modes of inheritance were considered. For the dominant 
inheritance model, family R1256 had several markers on chromosomes 6, 10, and 14 that 
had a two-point LOD score greater than 2.0. For this report, LOD scores greater than or 
equal to 2.0 were considered to be suggestive of linkage, with theta values equal to 0. For 
the multi-point analysis on this same family, only three markers in a 22 cM region of 
chromosome 14 had a LOD ≥ 2.0. For the other families, neither had LOD scores ≥ 2.0, 
using the dominant model. With a recessive model, no LOD scores ≥ 2.0 were identified 
in either of the families. Finally, a multi-point analysis using all seven families revealed a 
LOD score of 1.9 on chromosome 14.  
Interestingly, two previous IA studies have identified loci that overlap with this 
region on chromosome 14 (near rs17105585, rs11158743 and rs1956534). Ozturk et al. 
(2006) found significant linkage to chromosome region 14q23-31 in a Japanese family, 
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while Mineharu et al. (2008) found a SNP (rs767603) at Chr 14q23 that was significantly 
associated with IA in a larger cohort from Japan. However, no candidate genes were 
identified in either of these studies. This previous work has provided our laboratory with 
some preliminary data and the insight to employ a new approach for the continuation of 
this project. Any candidate variants on chromosome 14 will be of higher priority if they 
are detected through whole exome sequencing in our current study.  
 1.3.3 Utilizing Whole Exome Sequencing 
The introduction of next generation sequencing has provided a new way to 
explore disease-gene relationships, and has broadened the scope and success of genetic 
research. As mentioned previously, whole exome sequencing is a next generation 
technology that targets the protein-coding portion of the genome, of which we have the 
greatest understanding. Any variants that cause IA predisposition will likely impact the 
structure and proper functioning of specific proteins. As no strongly penetrant genes have 
been connected to the non-syndromic occurrence of IA, WES theoretically provides a 
way to visualize all the pathogenic exonic variants present in an individual affected by 
this disease. 
As with all sequencing technologies, several points need to be considered in a 
WES-based experiment. Different commercial platforms are currently available for 
massively parallel sequencing of the exome, including workflows by Illumina and 
Agilent. The steps of the Illumina HiSeq 2000 workflow will be discussed in section 2.3. 
Each platform is similar, but may yield varying coverage of the exome. Bamshad et al. 
(2011) reported that as much as 5-10% of the exome may have insufficient coverage or 
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may be skipped completely in a WES experiment, depending on the chosen commercial 
platform. The data analysis pipeline that is used following WES also greatly influences 
the identification of causal variants. Accuracy in alignment, quality control and variant 
calling is crucial, especially given the large amount of data produced from a single 
exome. At this point in time, only the detection of SNPs and some small 
insertion/deletions (INDELs) is possible using WES. Therefore, our focus lies within the 
current capabilities of this technology.  
Ultimately, WES may allow us to develop a better picture of the genetic make-up 
of familial IA patients than would be possible by traditional sequencing methods. By 
analyzing the exomes of multiple affected individuals within a family, I will be able to 
draw connections between shared genetic variants. The commercialization and increased 
use of WES in research has led to an abundance of user-friendly bioinformatics tools and 
variant databases that are now publically accessible. These tools will assist in evaluating 
variant pathogenicity and relevance to IA.  
 
1.4 Hypothesis  
 
Based on current knowledge of this disease, it is predicted that the multiplex 
families in this study have a genetic component contributing to the incidence of IA. I 
hypothesize that the families in this study will have one or more strongly penetrant 
variants that cause IA. Furthermore, I hypothesize that these genetic variants will be rare 
or novel, and located in the exome or intron/exon boundaries of the genome.  
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1.5 Objectives and Relevance of Research  
 
The purpose of my study is to identify genetic variants that cause IA 
susceptibility, through the study of families from Newfoundland and Labrador that have a 
strong predisposition. My study is designed around the following objectives:   
 
1. To design and implement a strategy to filter the genetic variants identified 
in the exomes of 12 IA patients from 2 multiplex families. 
2. To analyze filtered low, moderate and high impact variant lists separately, 
based on categorization by McGill University and Genome Quebec 
Innovation Centre. Also, to compare these variant lists to the results 
produced by NextGene
®
, and determine the potential utility of this desktop 
software in our laboratory.  
3. To use Sanger sequencing to validate prioritized genetic variants, and test 
for segregation in the families.  
4. To identify several candidate variants, discuss their potential relevance to 
the IA phenotype, and determine their prevalence in a NL population 
control cohort.   
 
Through the completion of this study, I hope to contribute to our growing 
understanding of the genetic etiology of IA. Due to genetic heterogeneity, there is likely 
to be more than one mode of inheritance for familial IA. The knowledge obtained from 
this research could lead to the identification of individuals with unruptured IAs, which 
may then be treated. Successful treatment can reduce the risk of hemorrhagic stroke and 
 38 
its complications in IA patients. As well, the identification of genetic risk factors could 
assist in genetic counseling of patients and their families. It is also possible that genetic 
variants identified through this study will have importance in other populations globally. 
Furthermore, my research may lead to further genetic studies involving the cohort of IA 
patients from Newfoundland and Labrador.   
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2. Materials and Methods 
2.1 Study Design, Patient Recruitment and Clinical Information  
 
To test my hypothesis, a research plan with corresponding rationale was designed 
(Figure 7). Step one of the methods, participant recruitment, was completed prior to the 
commencement of this project. The recruitment of IA patients for this study was a 
collaboration between Dr. Falah Maroun and neurosurgeons from Eastern Health, and Dr. 
Bridget Fernandez, chair of the Discipline of Genetics. Neurosurgeons in the Division of 
Surgery referred patients with both ruptured and unruptured IA. Diagnosis occurred 
through the use of computed tomography scan (CT) or magnetic resonance imaging 
(MRI) of the Circle of Willis. Eastern Health has the only unit of neurosurgery for 
Newfoundland and Labrador, thus providing us with a patient cohort from across the 
province.  
 Each affected individual was placed into one of three categories: familial, 
sporadic, or equivocal. Familial cases are patients who have at least one first or second-
degree relative with IA, and sporadic cases are patients with no known family history of 
the disease. Finally, patients are classified as equivocal if there is not yet enough 
evidence to determine whether their IA is sporadic or familial in nature. A three-
generation pedigree was taken for each participant. The active participation of IA patients 
was instrumental to the recruitment of additional affected and unaffected relatives to this  
study. The medical histories of any consenting relatives were reviewed, and they were 
offered screening of the Circle of Willis through computed tomography angiography, to 
identify any unknown cases of IA. A blood sample was collected from all affected and  
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Figure 7. Overall study design, with corresponding rationale. 
 
Abbreviations: gDNA = genomic DNA, NL = Newfoundland and Labrador, MUGQIC = McGill 
University and Genome Quebec Innovation Centre  
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unaffected study participants, for the extraction of DNA. Blood samples were sent to the 
Discipline of Genetics, where DNA extraction from whole blood was performed using 
the Promega Wizard
® 
Genomic DNA Purification Kit, which is described in detail in 
Appendix A. Genomic DNA was catalogued in the Woods Lab DNA Bank, and samples 
were stored at 4°C.  
 In addition, a thorough collection of phenotypic information was recorded for all 
affected participants (familial, sporadic and equivocal). This included the patient’s sex, 
age at diagnosis, whether diagnosis was made through clinical screening or following 
rupture, number of IAs, location of IA in vasculature, size of IA, age at rupture, and any 
treatments administered. The detailed phenotypes were provided to our laboratory, and 
could be highly valuable at the later stages of this study, for example for investigating the 
connection between genetic etiologies and the varying severity and presentation of the 
disease. For all study participants, any additional medical history was also documented. 
Several risk factors for IA were also recorded, including hypertension, smoking status 
and smoking history.  
As of April 2014, 137 affected individuals had been recruited to the study, 
including 99 familial IA patients and 396 of their unaffected relatives representing 53 
families. DNA samples are available for 92 of these familial cases. The remaining 
affected individuals were categorized as 33 sporadic IA patients and five equivocal cases. 
These individuals also consented to have a blood sample drawn for the purpose of DNA 
extraction. Eight of the participating families are of particular interest, as they each have 
three or more affected family members for whom DNA samples are available (Table 4).  
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Table 4. Families from NL cohort with more than three affected individuals. 
 
Family ID # of Reported Affected 
Family Members  
# Affected, with 
DNA available 
R1256 12 11 
R1276 4 4 
R1277 8 6 
R1352 11 9 
R1357 4 4 
R1381 5 3 
R1400 6 3 
R1888 5 4 
  
The number of reported affected family members is based on provided pedigrees and clinical data 
as of 2014. DNA was not available for several affected relatives who did not provide consent to 
participate in the research study. As well, several individuals were deceased prior to the 
commencement of patient recruitment.      
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2.2 Study Families and Mode of Inheritance  
 
For my thesis, I focused on two of the recruited families that have a particularly 
strong family history of the disease: R1256 and R1352. In this way, my thesis research 
has represented a pilot project of WES with our IA cohort. Family R1256 is a large 
kindred with origins in Happy Valley-Goose Bay (Figure 8, 9). In contrast, family R1352 
has origins in the St. Mary’s Bay region of the island (Figure 10). A detailed clinical 
summary of the affected participants is provided in Tables 5 and 6.  In addition to family 
history, several of these individuals have relevant modifiable risk factors, including 
cigarette smoking, hypertension, and alcohol use, which have been noted for their 
potential influence in IA development. All affected individuals were diagnosed between 
the ages of 29 and 79, with a mean age of initial diagnosis of 50.2 for R1256, and 54.9 
for R1352. In both families, the number of females with IA was greater than the number 
of males with the disease. In family R1352, eight females and three males were affected, 
and in family R1256, nine females and three males were affected.   
Given that clinical information was available for each family over several 
generations, predictions can be made regarding the mode of inheritance. The pedigree 
appearance for family R1256 is consistent with an autosomal recessive mode of 
inheritance, as most of the affected individuals (11/12) are in a single generation (Figure 
9). If there is incomplete penetrance, as well as unknown aneurysm diagnoses in 
deceased family members, the mode could also be autosomal dominant with variable 
penetrance. In family R1352, the presence of consanguinity affects interpretation of the 
pedigree. Two affected individuals in this pedigree (Z1496 and Z1495) are the parents of 
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eight children, and six of the children have the disease. Individual Z1495 has another son 
by a different partner, Z1507, who also has the disease phenotype. Given the 
consanguinity between Z1496 and Z1495, the mode of inheritance in this family could be 
either autosomal dominant or recessive. If the mode is autosomal dominant, all affected 
individuals could be either heterozygous or homozygous for the causative variant. For the 
purposes of our study, both modes of inheritance will be considered in the interpretation 
of genetic variants in these families. The complex nature of IA including penetrance and 
the influence of modifiable risk factors will be explored further in section 4.  
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Figure 8.  Geographic representation of families R1256 and R1352 in province of 
Newfoundland and Labrador. Adapted from NordNordWest (2009) 
with copyright permission, under Creative Commons license CC BY-SA 3.0.  
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Table 5. Phenotypic summary of affected family members from family R1256. 
 
Patient 
ID 
# of 
IAs 
Size of 
IA(s) 
Site of IA(s) 
 
Type of 
Treatment 
Given 
 
IA 
Rupture 
(Yes/No) 
Risk Factors & Known 
Medical History 
Z929 1 4.5 mm R-MCA No surgery 
(observation) 
No Hypertension, coronary 
artery bypass surgery 
Z1013 
 
2 Unknown; 
4.5x5.5 mm  
R-MCA x2 Clipping Yes Not available 
 
Z1390 
 
1 1.5x2.5 mm  A1-A2 Junction 
(L) 
No surgery 
(observation)  
No Hypertension, smoker,  
heart murmur 
Z1405 4 13-14 mm;  
4-5 mm; 2 
mm; 2 mm 
Paraophthalmic;  
L-paraclinoid;  
R-ICA x2 
Coiling No 
 
Ex-smoker, 
hypercholesterolemia, 
allergies, asthma, GERD, 
fibromyalgia 
Z1406 1 5x10 mm L-ACOMM Clipping Yes 
 
Hypertension, 
hyperlipidemia 
Z1441 1 3.6x3.2 mm L-ICA No surgery 
(observation) 
No Hypertension, smoker 
 
 
Z1448 1 1.5 mm R-MCA No surgery 
(observation)  
No Hypertension, ex-smoker, 
hypercholesterolemia 
 
Z1459 
 
2 7x8 mm;  
9 mm  
L-ACOMM;  
R-PICA 
Coiling; 
Clipping 
No Hypertension, ex-smoker, 
diabetes mellitus, obesity, 
asthma 
Z1471 
 
3 1.9x1.3 mm; 
2.4x1.7 mm; 
1.3x0.8 mm  
PCOMM; 
Bilateral Distal 
ICA; Unknown 
No surgery 
(observation)  
No Smoker 
Z1501 
 
1 3x4 mm  ACOMM No surgery 
(observation)  
No Hypertension, ex-smoker, 
hypercholesterolemia, 
diabetes mellitus, 
osteoarthritis, Burkitt’s 
lymphoma, diverticulosis 
Z1522 
 
1 10 mm  R-ICA Coiling No Smoker, hypothyroidism, 
migraines, reflux  
 
Abbreviations: ACOMM = anterior communicating artery, GERD = gastroesophageal reflux 
disease, ICA = internal carotid artery, L = left, MCA = middle cerebral artery, PCOMM = 
posterior communicating artery PICA = posterior inferior cerebellar artery, R = right  
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Table 6. Phenotypic summary of affected family members from family R1352. 
 
Abbreviations: AAA = abdominal aortic aneurysm, ACOMM = anterior communicating artery, 
COPD = chronic obstructive pulmonary disease, GERD = gastroesophageal reflux disease, ICA = 
internal carotid artery, L = left, MCA = middle cerebral artery, R = right  
 
 
Patient 
ID 
# of 
IAs 
Size of 
IA(s) 
Site of IA(s) 
 
Type of 
Treatment 
Given 
  
IA 
Rupture 
(Yes/No)  
Risk Factors & Known 
Medical History 
Z1039 2 10x7 mm; 
 3 mm 
L-ICA;  
R-Distal ICA 
Clipping No Hypertension 
 
 
Z1040 2 Unknown L-ICA x2 No surgery 
(observation)  
No Reflux, depression 
 
 
Z1495 
 
1 Moderate R-MCA Clipping Yes AAA, smoker, COPD 
 
 
Z1496 
 
2 Small;  
Small 
L-MCA;  
R-MCA 
No surgery 
(observation)  
No Smoker, heavy alcohol 
intake, Steele-Richardson 
Olszewski syndrome, COPD, 
peptic ulcer disease  
Z1497 1 Small Paraclinoid No surgery 
(observation)  
No Hypertension, 
hypercholesterolemia, back 
pain 
Z1507 1 2.8x4.8 
mm 
ACOMM No surgery 
(observation)  
No Smoker, myocardial 
infarction, atrial fibrillation, 
splenic artery 
pseudoaneurysm, alcoholic 
pancreatitis, back pain 
Z1508 2 Small;  
4 mm 
L-MCA;  
R-ICA 
Coiling No 
 
Smoker, GERD 
 
 
Z1533 1 9.4x5.6 
mm 
R-MCA Clipping No 
 
Smoker 
 
 
Z1651 1 1.5-2 mm L-Paraophthalmic  No surgery 
(observation)  
No Not available  
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Several family members were subsequently selected for whole exome sequencing. 
For a single complete WES run, six samples can be accommodated. For this pilot project, 
12 affected individuals were chosen between both families for a total of two runs: five 
from R1256 (Figure 9), and seven from R1352 (Figure 10). Where possible, a diverse 
array of relatives was selected for sequencing. Affected family members who are more 
distantly related, such as cousins, can be highly informative as they share fewer variants 
than closely related individuals, such as siblings (Bamshad et al., 2011). Often, WES 
experiments involve the inclusion of at least one unaffected relative as a control sample 
to help elucidate pathogenic variants. Several features of IA as a disease prevented the 
use of this methodology. IA is a late-onset condition and within each of these two 
families the penetrance is unknown. It is possible that an included “unaffected” relative 
could develop IA later in life, or may carry an IA risk allele but not display disease 
characteristics due to decreased penetrance. However, many WES studies do not have 
access to multiplex families of this size. The comparison of five or more affected exomes 
within a single family is expected to assist in the identification of shared rare variants, 
and should help overcome the lack of an unaffected control exome.  It is expected that the 
affected family members will have a shared genetic risk factor. Our laboratory has also 
performed exome sequencing for other genetic diseases including colorectal cancer and 
idiopathic pulmonary fibrosis; therefore we have access to data from unrelated NL 
samples that can be used as controls in this study if necessary.   
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2.3 Whole Exome Sequencing and Bioinformatics Analyses  
 
Whole exome sequencing and preliminary bioinformatics analyses outlined in this 
section were completed at the McGill University and Genome Québec Innovation Centre 
(MUGQIC). The following descriptions are adapted from instructional videos and 
materials provided by MUGQIC (MUGQIC Bioinformatics, 2014; Schwartzentruber, 
2012), technical documents from Illumina
®
, and a review by Bamshad et al. (2011).  
 2.3.1 Library Preparation and Sequencing   
 Initially, it is necessary to amplify and isolate the exons and intron/exon 
boundaries of the target DNA samples. MUGQIC employs the “Exome Seq – Sure Select 
Agilent” protocol for shotgun sequencing library preparation. DNA is required to meet 
specific quality standards, including sample concentration and volume. For this project, 
concentrations were adjusted to 100 ng/μl, and 70 μl of each sample was provided. Each 
DNA sample was sheared into fragments of approximately 200 base pairs (bp) in length, 
through ultrasonication. Fragments were then ligated with 5’ and 3’ adapters to repair the 
sequence ends, and amplified through PCR. Next, a hybridization step was used to 
capture the exome; ligated fragments were hybridized to biotinylated RNA baits, which 
are designed to target the exon sequences. Baited fragments were “pulled down” with 
streptavidin covered magnetic beads, which bind to biotin. This step separated out any 
uncaptured non-coding DNA.   
For our study, massively parallel sequencing was completed using an Illumina
®
 
HiSeq 2000 sequencer. Ligated fragments were loaded into a flow cell, where they were 
bound to complementary oligos. Bridge amplification was used to create sample clusters, 
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each of which produced a paired-end read. The Illumina
®
 system utilizes sequencing by 
synthesis (SBS) technology to generate reads, which are lengths of A, T, C and G bases.  
Base calls were made using the Illumina
®
 CASAVA pipeline.  
 2.3.2 Alignment and Quality Control Methods 
 The next steps in the WES process concern data analysis, which is integral to the 
accurate annotation and interpretation of genetic variants. Raw reads were trimmed and 
adapters were removed, so that filtered reads were at least 50 base pairs in length. 
Sequencing reads were then aligned to the human reference genome version GRCh37 
(hg19), using Burrows Wheeler Alignment (BWA) software version 0.6.2 (H. Li & 
Durbin, 2009). Several quality control methods were then employed to ensure high 
sequence quality. This included the realignment of reads in areas with multiple base 
mismatches, which was done with Genome Analysis Toolkit (GATK) software version 
2.7.2 (McKenna et al., 2010). During the sequencing process, PCR duplicates can occur 
when some sheared fragments become localized to multiple beads of the flow cell. This 
results in over-amplification of some regions of the exome. Duplicate reads were marked 
and excluded using Picard software version 1.108. Overall base quality was then 
reassessed, in preparation for variant calling and annotation.  
 2.3.3 Variant Calling and Annotation  
 Any discrepancies between the exome sequence and reference genome sequence 
were classified as genetic variants. Both SNPs and INDELs were detected using the 
programs samtools and bcftools. Samtools (version 0.1.19) (H. Li et al., 2009) collects 
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summary information, and bcftools completes the actual variant calling. Through the use 
of Bayesian statistics, information such as the number of reads and sequence quality was 
considered, to predict whether a mismatch was a true variant or a false-positive call. 
Bcftools was then used to transform this information into the variant call format (VCF) 
(H. Li, 2011). The ANNOVAR program (K. Wang, Li, & Hakonarson, 2010) uses these 
VCF files to annotate the variant type - for example: non-synonymous SNPs, nonsense, 
frameshift, splicing, etc. This program includes SnpSift software (Cingolani, Patel et al., 
2012) to provide annotations from dbSNP (Smigielski, Sirotkin, Ward, & Sherry, 2000). 
As well, ANNOVAR includes annotations from the Database for Non-Synonymous 
SNPs Functional Predictions (dbNSFP version 2.0). This database integrates the scores 
from several functional predictive algorithms, for all possible non-synonymous SNPs in 
the human genome (Liu, Jian, & Boerwinkle, 2013). Our results included scores 
compiled from SIFT (Kumar, Henikoff, & Ng, 2009), Polyphen2 (Adzhubei et al., 2010), 
LRT (Chun & Fay, 2009) and MutationTaster (Schwarz, Rodelsperger, Schuelke, & 
Seelow, 2010). These four algorithms each provide a predictive score that can be used to 
assess the likelihood that a particular amino acid change is pathogenic. As well, PhyloP 
(Siepel & Haussler, 2004), GERP (Cooper et al., 2005) and SiPhy (Garber et al., 2009) 
scores were included, which can be used to predict the evolutionary conservation of an 
amino acid change. Finally, the SnpEff software (version 3.3) was used to predict the 
effect or impact of a variant on an overall gene (Cingolani, Platts et al., 2012). Variants 
were placed in one of three categories: high, moderate or low impact (Table 7).  
Bioinformaticians at MUGQIC grouped the VCF files and annotations for each of 
our exomes by family, and also by impact. Thus, we were provided with separate high, 
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moderate and low impact lists for R1256 and R1352. As an initial filtering step, the 
bioinformatics team at MUGQIC recommended the removal of variants with a read depth 
lower than 10 in all exomes from a single family. This step is a quality control measure 
used in next generation analysis to remove false-positive calls and variants with low 
coverage. The VCF files were subsequently transferred to Microsoft Excel spreadsheets 
for ease of data retrieval and filtering. These lists included any genetic variants that were 
detected in one or more exomes from a single family.  
For the purposes of my study, I will be filtering all three variant impact 
categories, but considering only variants of high and moderate effect for validation and 
further analysis at this time (Table 7). It is expected that a variant contributing to IA 
development and rupture risk would have a significant impact on both the gene and 
protein level. To deal with this large amount of data, the next step in my methodology 
involved the development of a variant filtering strategy. 
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Table 7. Variant impact categories. 
 
 Variant Types Included  
High Impact Splice site acceptor, splice site donor, start-
lost, exon deleted, frame-shift, stop-gained, 
stop-lost, rare amino acid substitution 
 
Moderate Impact Non-synonymous coding (missense), 
codon change, codon insertion, codon 
deletion, codon change plus codon 
insertion, codon change plus codon 
deletion, 5’UTR deleted, 3’UTR deleted 
 
Low Impact Synonymous start, non-synonymous start, 
start-gained, synonymous coding, 
synonymous stop  
 
 
Criteria determined by McGill University and Genome Quebec Innovation Centre, through the 
use of the SNPEff software (Cingolani et al., 2012). 
 
Abbreviations: UTR = untranslated region 
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2.4 Filtering of Low, Moderate, and High Impact Variants   
 2.4.1 Previously Identified Candidate Genes for IA   
 As a first step, I searched the moderate and high impact lists for variants in genes 
that have been significantly associated with IA in previous studies. I selected a recent 
review article by Tromp et al. (2014) that lists the statistically significant associations 
with IA that have been identified in published GWAS or candidate gene association 
studies. Specifically, the 20 genes found in or near these chromosomal loci are 
highlighted in Table 8. I used the list of genes featured in this article to query the 
moderate and high impact lists for each family. Any variants identified in IA candidate 
genes would be highlighted and further analyzed for their relevance to this study.  
 2.4.2 Variant Filtering Strategy  
In order to identify genetic variants that could play a role in familial IA, I developed a 
strategy to filter out variants that were likely extraneous in this study. This strategy was 
designed based on a review of WES publications, and considerations regarding the 
features of IA. First, I began by using the annotations provided by MUGQIC to filter the 
collection of low, moderate, and high impact variants from all 12 exomes. As only 
affected individuals were included in this analysis, the assumption was made that any 
variants of interest would be shared by all exomes from a single family. To account for 
the possibility of phenocopies and sequencing coverage error, I chose to also keep 
variants that were shared by 6/7 members of R1352, or 4/5 members of R1256. This step 
is not a common practice in family-based WES studies, but I believed it would be 
suitable considering the role of environmental factors in IA development.  
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Table 8.  Summary of genes found in or near variants that have been significantly 
associated with IA.  
 
Gene Chr 
Region  
Associated 
SNPs  
Variant Context 
(Proximity to Gene)  
Initial Reference for 
Association  
ACE 17q23.3 rs4646994 intronic Chen et al. (2013) 
CDKN2B-AS1 9p21 *rs1333040 
*rs10757278 
*rs6475606 
intronic 
intergenic 
intronic 
Bilguvar et al. (2008) 
Helgadottir et al. (2008) 
Foroud et al. (2012) 
COL1A2 7q21 *rs42524 intragenic (p.P549A) Yoneyama et al. (2004) 
COL3A1 2q32 *rs1800255 intragenic  
(p.A698T) 
Hua et al. (2008) 
CNNM2 10q24.3 rs12413409 intronic Yasuno et al. (2010) 
EDNRA 4q31.23 *rs6841581 intergenic Yasuno et al. (2011) 
ELN 7q11.2 rs8326 3’ UTR Akagawa et al. (2006) 
FGD6 12q22 *rs6538595 intronic Yasuno et al. (2011) 
HSPG2 1p36.1 *rs3767137 intronic Ruigrok et al. (2006) 
IL6 7p15 *rs1800796 intergenic Sun et al. (2008) 
JDP2 14q24 rs175646 intronic Krischek et al. (2010) 
KLK8 19q13.3 rs1722561 intronic Weinsheimer et al. (2007) 
LIMK1 7q11.2 rs6460071 intergenic Low et al. (2011) 
RRBP1 20p12.1 *rs1132274 intragenic  (p.R891L) Yasuno et al. (2011) 
SERPINA3 14q32 *rs4934 intragenic (p.A9T) Slowik et al. (2005) 
SOX17 8q11.23 *rs10958409 
*rs9298506 
intergenic (5’end) 
intergenic (3’) 
Bilguvar et al. (2008) 
Bilguvar et al. (2008) 
STARD13 13q13 rs9315204 intronic Yasuno et al. (2010) 
TCN2 22q12 rs1801198 intragenic (p.R259P) Semmler et al. (2008) 
TNFRSF13B 17p11.2 rs4985754 
rs2274892 
rs34562254 
rs11078355 
promoter 
intronic 
intragenic (p.P251L) 
intragenic, synon. 
Inoue et al. (2006) 
Inoue et al. (2006) 
Inoue et al. (2006) 
Inoue et al. (2006) 
VCAN 
(CSPG2) 
5q14 *rs173686 
*rs251124 
intronic  
intronic  
Ruigrok et al. (2006) 
Ruigrok et al. (2006) 
 
 58 
Abbreviations: Chr = Chromosome, SNP = single nucleotide polymorphism, synon = 
synonymous 
 
*These variants were also reported in a meta-analysis by Alg et al. (2013) as being significantly 
associated with IA. They used random-effects and sensitivity analyses to determine the 
robustness of previously-reported associations from candidate gene association studies and 
GWAS for IA.  
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 Since IA is not a highly common disorder in the general population, I chose to 
focus on variants that were not previously reported, or had a low minor allele frequency 
(MAF) in dbSNP (Smigielski et al., 2000). The exclusion of variants with a MAF greater 
than or equal to 1% is commonly used in the study of recessive disorders, while a cutoff 
lower than 1% may be applied in autosomal dominant cases (Bamshad et al., 2011). To 
avoid an overly stringent interpretation, the 1% cutoff was maintained in this study. 
Bamshad et al. (2011) referred to this step as “discrete filtering”, to provide a manageable 
list of prioritized rare variants that can be further assessed for functional relevance. 
Variants with a MAF ≥1% in a control set of 848 exomes from Genome Quebec were 
also excluded.  
While this first phase of filtering eliminated a large number of variants, further 
reduction of the data was necessary. In recent years, the accessibility and decreased cost 
of WES has led to its frequent use in gene discovery. As a result, a number of exome 
variant databases have emerged, most notably, the NHLBI Exome Variant Server and the 
ExAC Browser. The most recent National Heart Lung and Blood Institute (NHLBI) 
dataset includes 6,503 exomes from American projects targeting heart, lung and blood 
disorders (Exome Variant Server, 2015). The ExAC Browser from the Broad Institute 
currently contains exome data from 60,706 individuals, who were sequenced in various 
large-scale genetics projects internationally (Exome Aggregation Consortium, 2015). 
This browser, in particular, provides an invaluable resource of control exomes with 
variant frequencies. Similarly, Ensembl is a continually updated genome browser that 
unites frequency data from dbSNP, 1000 Genomes (1000 Genomes Project Consortium et 
al., 2012) and NHLBI, as well as individual laboratories (Cunningham et al., 2015).  
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After the first phase of filtering, I manually searched for the presence of remaining 
variants in these three browsers, beginning with ExAC. Any variants with a reported 
MAF greater than or equal to 1% were eliminated. A flow chart clearly depicting these 
two phases of filtering methodology is provided in Figure 11. 
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Figure 11. Preliminary variant filtering strategy for 12 IA exomes. 
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2.5 NextGene
® 
Software  
 
In addition to the data analysis pipeline used by MUGQIC, I performed some 
general bioinformatics analysis of our raw exome data using the NextGene
® 
desktop 
software produced by SoftGenetics
®
. NextGene
® 
was designed to enable researchers to 
quickly assess genetic variants from NGS data, without additional bioinformatics support. 
This stage of my project was completed prior to receiving variant calls from MUGQIC, 
mainly to evaluate the ease of use and applicability of this platform for use in exome 
analysis in our laboratory.  
In spring 2014, MUGQIC uploaded the raw exome data for this project to the 
Nanuq external server. I was able to access and download these .fastq files, for the 
forward and reverse direction of each exome, to a desktop computer in the Woods 
laboratory. Files in the .fastq format can be directly uploaded to NextGene
®
, where they 
are subsequently converted to .fasta files. The forward and reverse files for each exome 
were then aligned to the human reference genome version GRCh37 (hg19). Following 
alignment, the software offers several options for quality control, such as selection of an 
optimal sequencing coverage cut-off. The default parameters were chosen for my 
analysis, to assess the basic functioning of the software. The coverage option was set to 
>10x for each read, and reads were required to be at least 50 base pairs in length. The 
software recognizes discrepancies between the exome and reference genome, which are 
called as variants.  
With regards to variant annotation, NextGene
® 
has a Track Manager tool, which 
enables users to import information from different variant databases such as dbSNP, and 
 63 
1000 Genomes. This information includes the rs ID number for previously reported 
variants, the overall minor allele frequency, and frequencies specific to different 
populations. Annotations from dbNSFP 2.0 (Liu et al., 2013) can also be imported, 
including scores retrieved from SIFT (Kumar et al., 2009), Polyphen2 (Adzhubei et al., 
2010), LRT (Chun & Fay, 2009), MutationTaster (Schwarz et al., 2010), 
MutationAssessor (Reva, Antipin, & Sander, 2011) and FATHMM (Shihab et al., 2013). 
Values for PhyloP (Siepel & Haussler, 2004), GERP (Cooper et al., 2005) and SiPhy 
(Garber et al., 2009) are also accessible by NextGene
®. 
The variant list for a single exome 
may be queried through the use of these various tracks. For example, variants with 
Polyphen2 scores in the “probably damaging” or “possibly damaging” categories can be 
selected, which effectively eliminates scores that are predicted to be benign. Each 
predictive algorithm category can be filtered in this manner, to tailor a variant list to 
reflect a specific study design.  
 The most relevant application provided by NextGene
®
 for family-based studies is 
the variant comparison tool (VCT). This tool allows a user to compare variant calls and 
annotations from multiple exomes. The VCT also provides a filter to view heterozygous 
or homozygous variants exclusively, as well as the option of specifying family 
relationships and affection status. For my project, I used this tool to compare the five 
exomes from R1256 with two unrelated control exomes selected from other projects in 
the Woods Laboratory. One exome was from a familial colorectal cancer patient 
(CRC:RD218), and the other was from an idiopathic pulmonary fibrosis patient 
(IPF:Z37). I was able to cross-reference variants that were found in all exomes from 
family R1256, but not in these controls. Both heterozygous and homozygous variants 
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were queried, to reflect the unknown inheritance pattern of IA in this family. All variants 
with an unreported MAF or value less than 1% were kept in the analysis. I also used the 
VCT to compare all seven exomes from R1352 with these two control exomes. As a 
second option, I compared the exomes of the four siblings (Z1039, Z1040, Z1497, 
Z1508) from R1352 with the selected controls. These closely related individuals were 
selected due to potential genetic heterogeneity within the extended family. As well, this 
option allowed me to visualize variants shared by four, five or six relatives, which 
provided a greater dataset for this large family. The resultant variant lists were reviewed 
to locate any genes previously described in IA association studies. As well, these lists 
were compared to the group of candidates that passed my initial variant filtering strategy. 
Any overlap would provide a level of increased confidence in the variant calls made by 
MUGQIC.   
 
2.6 Additional Variant Prioritization  
 
Following the filtering strategy outlined in section 2.4, a limited number of 
candidate variants remained for each family. From this point forward, I only considered 
moderate and high impact variants for further analysis. During the filtering stage of my 
project, the article “Lessons learned from whole exome sequencing in multiplex families 
affected by a complex genetic disorder, intracranial aneurysm” by Farlow et al. (2015) 
was released. This study summarized preliminary data from a whole exome sequencing 
project by the Familial Intracranial Aneurysm Study investigators. As mentioned 
previously, they used WES to identify a list of 68 variants of interest across seven 
families, which are potentially involved in IA risk. Due to the timely release of this 
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article and relevance to my research, I decided to compare their list of 68 variants to my 
lists of filtered moderate and high impact variants.  
Lastly, the number of moderate impact variants for R1256 was still high after 
filtering, so further analysis was necessary to achieve a manageable number for the scope 
of my thesis project. Moderate impact variants that were found in 5/5 exomes, and were 
unreported in dbSNP and ExAC, were selected for further consideration in this study. 
Additional variants from this family may be validated as part of future research.  
 
2.7 Validation and Segregation Analyses  
 
 In order to verify that the moderate and high impact candidate variants identified 
by WES were not false-positives, Sanger sequencing was used for the validation stage of 
this project. Additional affected individuals from R1256 were included as well (Table 9). 
This step allowed me to assess whether a variant was present in all or most relatives with 
IA. Any variants that did not appear in the majority of affected individuals were 
discarded from further analysis.  
 After a number of top candidates were identified, a selection of unaffected 
relatives were also sequenced, to provide a better picture of the possible mode of 
inheritance and penetrance. To further assess top candidates, Polyphen2, SIFT and GERP 
scores were also evaluated as a prediction for pathogenicity, as they were readily 
available for most non-synonymous variants. Polyphen2 is an algorithm that is used to 
predict the impact of an amino acid substitution on the overall protein, and its function 
and structure (Adzhubei et al., 2010). Scores can range from 0-1, or “benign” to 
“probably damaging”. Intermediate scores on this scale may be classified as “possibly  
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Table 9. Affected individuals who were Sanger sequenced in each family. 
 
R1352  R1256 
Z1039 Z929 
Z1040 Z1013
+
 
Z1497 Z1390
+
 
Z1507 Z1405 
Z1508 Z1406 
Z1533 Z1441 
Z1651 Z1448 
Z1496
+
 Z1459
+
 
Z1495
+
 Z1471
+
 
 Z1501
+
 
 Z1522
+
 
    
+
These individuals were not used in WES analysis, but were included in the validation stage of 
the project, when prioritized variants were sequenced. DNA for Z1496 and Z1495, in family 
R1352, did not produce successful Sanger sequencing results for the majority of tested variants, 
due to low quality DNA extraction. 
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damaging”. Sorting Intolerant From Tolerant (SIFT) provides a similar prediction, as 
scores from 0-0.05 are considered to be predictive of “damaging” or deleterious 
substitutions. Scores above 0.05 to 1 are classified as “tolerated” or benign (Kumar et al., 
2009). Genome Evolutionary Rate Profiling (GERP) scores can range from -12.3 to 6.17, 
with scores greater than 3.00 being indicative of evolutionary conservation of an amino 
acid, as a measure of functional constraint (Cooper et al., 2005). 
 
2.8 Sanger Sequencing Protocol  
 
Multiple steps are involved in the execution of a successful Sanger sequencing 
experiment. The following standard protocols are used by the Woods Laboratory, and 
were consistently followed throughout this project.  
 2.8.1 Polymerase Chain Reaction  
Prior to PCR, highly concentrated genomic DNA samples were diluted to aliquots 
of approximately 50 ng/μl. Each individual reaction contained a mixture of 1.5 μl of 10x 
PCR reaction buffer, 0.375 μl of deoxyribose nucleotide triphosphates (dNTPs) at 
100ng/μl, 0.5 μl of forward primer at 10 μM, 0.5 μl of reverse primer at 10 μM, 0.75 μl of 
MgCl at 50 Mm, 0.15 μl of Platinum Taq Polymerase, 10.225 μl of distilled H2O, and 1 
μl of genomic DNA. A negative control, which excludes genomic DNA, was included in 
each PCR procedure. Master PCR mixes were prepared in 0.5 or 1.5 ml microcentrifuge 
tubes, and individual reactions were pipetted into 96-well PCR plates. Plates were 
covered with plastic PCR caps, vortexed, and centrifuged for 20 seconds. Plates were 
then placed in either an Eppendorf Mastercycler
®
 or Biometra
®
 T1 thermocycler, which 
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were programmed to a specific protocol. Prior to amplification of patient DNA, protocols 
were optimized for each primer set, using control DNA. Protocol design was based on the 
melting temperature of primers, and experimentation with different known procedures. 
Primer sequences and corresponding thermocycler protocols are described in Appendix 
B.  
Following amplification, PCR reactions were verified using agarose gel 
electrophoresis. Agarose gels were prepared using a mixture of 50 ml of 1x TAE buffer 
and 1 g of Ultrapure agarose in an Erlenmeyer flask. This mixture was then heated in a 
microwave for 75 seconds. Subsequently, 3.75 μl of SYBR® Safe DNA Gel Stain was 
added to the mixture to allow the visualization of the gel under UV light. The gel mixture 
was poured into a mold, and combs were placed to create wells for PCR products. To 
prepare for electrophoresis, 3.5 μl of 5x loading dye was mixed with 3 μl of each PCR 
product, and these samples were then pipetted into individual wells. As a reference point, 
the first well of each row was filled with 3.5 μl of loading dye and 1 μl of 100 bp DNA 
ladder. The agarose gel was then placed in a gel chamber and covered with 1x TAE 
buffer. A power source was connected to the chamber and each gel was run at 120 V for 
25-30 minutes. Gels were viewed under UV light using an AlphaImager EP light cabinet, 
to determine if DNA was successfully amplified, and confirm that reactions were not 
contaminated.  
 2.8.2 ExoSAP  
The next step in preparation for Sanger sequencing involves the removal of excess 
dNTPs, using a mixture of exonuclease and shrimp alkaline phosphatase (ExoSAP). Each 
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reaction consisted of 0.5 μl of exonuclease, 0.5 μl of shrimp alkaline phosphatase, 7.5 μl 
of distilled H2O, and 8 μl of PCR product. The master mix of ExoSAP was prepared in a 
1.5 ml microcentrifuge tube, over ice. Individual reactions were pipetted into standard 
PCR plates, and capped. Plates were mixed with a vortex, and centrifuged for 20 seconds. 
Plates were then placed on a thermocycler, which was programmed to the “ExoSAP” 
protocol, and is described in detail in Appendix C. 
 2.8.3 ABI Cycle Sequencing  
Following PCR product clean-up with ExoSAP, ABI cycle sequencing reactions 
were prepared. Each reaction contained 0.5 μl of ABI cycle sequencing mix, 2 μl of 5x 
sequencing buffer, 0.67 μl of 10 μM primer, and 15.83 μl of distilled H2O. Two reaction 
mixtures were created for each PCR product, one using a forward primer, and one using a 
reverse primer. Each 19 μl mixture, and 4 μl of PCR product, was added to a well of a 96-
well sequencing plate. Plates were capped, mixed with a vortex and centrifuged for 30 
seconds at 300 rpm. Plates were then placed in a thermocycler, and programmed to the 
“ABIseq” protocol, as described in Appendix C.  
The next step was to complete ethanol precipitation of the cycle sequencing 
reactions. After removing the plates from the thermocycler, 65 μl of 95% EtOH and 5 μl 
of 0.125 mM EDTA was pipetted into each well. Plates were re-capped, mixed quickly 
with a vortex, and centrifuged for another 30 seconds at 300 rpm. Plates were placed in 
the refrigerator at 4°C for 30 minutes, or alternatively, covered at room temperature, 
overnight. Next, plates were centrifuged for 30 minutes at 3000 g. Caps were removed 
from the plates, which were then inverted to remove the ethanol. Plates were inverted and 
 70 
placed on paper towel in the centrifuge, where they were spun at 300 rpm for 30 seconds 
to remove any excess ethanol. A multichannel pipette was then used to add 70% EtOH to 
each well. Plates were capped and centrifuged for 15 minutes at 3000 g. Once again, 
plates were inverted to remove excess ethanol, and blotted on paper towels. The plates 
were then allowed to dry for 30 minutes in a drawer at room temperature. Finally, 10 μl 
of deionized formamide (HiDi) was pipetted into each well. A clean septa was placed 
onto each plate, which was then vortexed and centrifuged briefly before being placed on 
a thermocycler set to the “Denature” program (Appendix C).  
 Finally, plates were loaded onto an ABI 3130 Cycle Sequencer. Each sequencing 
run, which covers two columns of a 96-well plate, is approximately one hour in length. 
Following sequencing, result files were uploaded to the Sequencing Analysis desktop 
software. Sequencing Analysis files were then opened using the Sequencher 5.0 program, 
which allows visualization of chromatograms and corresponding base calls.  
 
2.9 Population Control Testing  
 
 Following Sanger sequencing of prioritized variants, select top candidate variants 
were Sanger sequenced in a control cohort of 100 individuals representing the 
Newfoundland and Labrador population. Any variants with a high frequency in NL 
population controls are unlikely to be causative in this study, as some polymorphisms 
with a low MAF globally may have an increased prevalence localized to this province. 
Only 100 controls were used, as we were only interested in determining whether selected 
candidate variants are common, as opposed to estimating population frequency. The 
control DNA samples are part of the Newfoundland Colorectal Cancer Registry 
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(NFCCR) project. They represent residents from throughout the province who had no 
medical history of cancer, and were recruited through random-digit dialing (P. Wang et 
al., 2009).  
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3. Results  
3.1 Variant Calls by MUGQIC 
 3.1.1 Data Summary Following Variant Calling   
 Following WES and initial bioinformatics analysis, MUGQIC provided a total of 
six variant lists for the IA cohort, as well as some general statistics regarding sequencing 
coverage and run metrics for the exomes. For the 12 IA exomes, 40-63 million reads 
were generated per library. On average, the ratio of surviving reads following trimming 
to the number of raw reads from the sequencer was 91.85% for the 12 exomes. The mean 
coverage of the whole genome was 2.8% (total number of aligned reads/size of the 
genome). Approximately 97% of the bases in the capture region of the exome had a read 
depth of at least 10x.  
 As an initial requested filtering step, MUGQIC generated lists that contained only 
variants with a read depth above 10, across all exomes within a family. The low impact 
category contained the most variants, with 10,899 low impact variants detected in family 
R1256, and 9,324 in R1352. These values include variants found in any member of a 
family.  As expected, the lists of moderate and high impact variants were extensive; 
8,401 moderate and 339 high impact variants were called in the R1352 exomes. 
Similarly, 9,814 moderate and 410 high impact variants were called in family R1256. 
Throughout my results, the archived genome browser GRCh37.p13 from Ensembl was 
used to fill in any incomplete variant annotations from the MUGQIC variant lists. This 
measure was taken to avoid error, as the GRCh37 version of the human reference genome 
was used for read alignment.  
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3.2 Initial Variant Filtering  
 3.2.1 Candidate Genes from Previous Studies  
  Initially, I searched both the moderate and high impact lists from each family for 
the presence of genes found in or near regions that had been significantly associated with 
IA, as reviewed by Tromp et al. (2014). A total of 20 genes were identified from known 
candidate gene and genome-wide association studies of IA, and were summarized in 
Table 8. My results were interpreted with the knowledge that these studies are reporting 
statistical association, and not causation between certain SNPs and the IA phenotype. 
Associated SNPs may be in linkage disequilibrium with a SNP in another gene, or may 
possibly impact a molecular pathway involved in IA development.  
 In both families (R1256 and R1352) none of the 20 candidate genes were detected 
in the high impact variant lists. However, in the moderate impact lists, there were several 
variants identified within these genes. Notably, 10 missense variants in IA-associated 
genes were shared between the two families, and had been previously reported in dbSNP 
(Table 10). Some of these variants were shared by multiple exomes within a single 
family, whereas others were found in only two or three affected individuals, and are not 
likely implicated in the IA phenotype. All 10 variants were assessed in the Broad 
Institute’s ExAC Browser for minor allele frequency. The lowest MAF for one of these 
entries was 20.5%, for the RRBP1 variant rs1132274. Therefore, all of these variants are 
very common in the general population and were assumed to be non-pathogenic.  
 Additionally, there were several variants that were detected in only one of the 
study families. In R1256, 4 missense variants in the HSPG2 gene were called. One of 
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these variants, rs2291827, had a MAF value above 17% in the ExAC Browser. The other 
three variants included: rs139500146 (MAF=1.07%), rs114851469 (MAF=1.10%) and 
rs116788687 (MAF=1.76%), all of which had frequencies below 2%. These variants 
were only detected in 1 or 2 exomes out of 5, and were unlikely to be causative of IA. A 
missense variant in TNFRSF13B (rs34562254) was identified in 1 exome from R1256, 
and had a MAF of 14.2%. Finally, all 5 exomes were heterozygous for rs3625 in the 
JDP2 gene, which had a MAF value of 53% in the ExAC Browser.  
 In R1352, 7 missense variants and 1 inframe insertion were detected, which were 
not shared by the R1256 exomes. Two different missense variants in HSPG2 were 
identified: rs17459097 (MAF=4.2%) and rs146309392 (MAF=0.07948%). Despite its 
low population frequency, rs146309392 was not pursued as a candidate variant as it was 
only present in 1/7 exomes. Two common variants in TCN2, 1 in FGD6, and 1 in VCAN 
were also detected, but were also only present in a single family member. Three family 
members also shared a heterozygous inframe insertion in SOX17, which has not been 
previously reported in dbSNP.  
Finally, 4/7 exomes were heterozygous for rs72553883 in the TNFRSF13B locus, 
which has an allele frequency of 0.536%, and was found in 648/120,888 alleles from the 
ExAC Browser cohort. This variant could be explored further in future studies, though it 
does not segregate completely in this family. Functionally, TNFRSF13B has a potential 
role in immunity (Tromp et al., 2014). Four SNPs near or within this gene were 
significantly associated with IA in a Chr 17-specific exploration of IA cases and controls 
by Inoue et al. (2006). None of the variants in IA-associated genes were categorized as 
rare and shared by most exomes within a family, and thus were not pursued as part of this  
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Table 10. Variants in IA-associated genes detected in families R1256 and R1352. 
 
Gene Variant Details 
(rs# from dbSNP) 
Family (# 
Exomes with 
Variant)  
# Het / # Hom for 
Minor Allele / # Hom 
for Reference Allele 
MAF in ExAC 
Browser  
(alleles) 
COL1A2 c.1645C>G,  
p.P549A 
(rs42524) 
R1352 (7/7) 
R1256 (5/5) 
R1352: 1 / 6 / 0 
R1256: 4 / 1 / 0 
76.9% 
(93340/121334) 
COL3A1 c.2092G>A, 
 p.A698T 
(rs1800255) 
R1352 (4/7) 
R1256 (2/5) 
R1352: 2 / 2 / 3 
R1256: 2 / 0 / 3 
32%  
(22129/69064) 
ELN c.1222G>A,  
p.G408S 
(rs2071307) 
R1352 (5/7) 
R1256 (2/5) 
R1352: 5 / 0 / 2 
R1256: 2 / 0 / 3 
32.6% 
(39600/121386) 
RRBP1 c.2672G>T,  
p.R891L 
(rs1132274) 
R1352 (4/7) 
R1256 (4/5) 
R1352: 4 / 0 / 3 
R1256: 4 / 0 / 1 
20.5%  
(23922/116400) 
c.1829T>A, 
 p.L610H 
(rs6034867) 
R1352 (7/7) 
R1256 (5/5) 
R1352: 0 / 7 / 0  
R1256: 0 / 5 / 0 
*99.9%  
(86841/86848) 
STARD13 c.45C>G,  
p.N15K 
(rs876133) 
R1352 (3/7) 
R1256 (1/5) 
R1352: 2 / 1 / 4 
R1256: 1 / 0 / 4 
44.1%  
(5427/12302) 
VCAN c.5477G>A, 
p.R1826H 
(rs188703) 
R1352 (6/7) 
R1256 (5/5) 
R1352: 5 / 1 / 1 
R1256: 3 / 2 / 0 
38.1%  
(45930/120534) 
c.1045A>G,  
p.K349E 
(rs61749613) 
R1352 (1/7) 1 / 0 / 6 3.2%  
(3771/119722) 
TCN2 c.67A>G,  
p.I23V 
(rs9606756) 
R1352 (1/7) 0 / 1 / 6 11.7%  
(14139/121344) 
c.962C>T,  
p.S321F 
(rs9621049) 
R1352 (1/7) 1 / 0 / 6 11.2% 
(13582/121384) 
TNFRSF13B c.542C>A,  
p.A181E 
(rs72553883) 
R1352 (4/7) 4 / 0 / 3 0.54% 
(648/120888) 
c.752C>T,  
p.P251L 
(rs34562254) 
R1256 (1/7) 1 / 0 / 4 14.2%  
(16736/118038) 
FGD6 c.2255G>T,  
p.R752L 
(rs117209224) 
R1352 (1/7) 1 / 0 / 6 0.80% 
(966/121370) 
SOX17 c.68_69insGCACCA 
p.Q1325_H1326insQH 
(Unreported) 
R1352 (3/7) 3 / 0 / 4 N/A 
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HSPG2 
 
 
 
 
 
 
 
 
 
 
 
 
 
HSPG2, 
continued 
c.10918G>A, 
p.V3640I 
(rs17459097) 
R1352 (2/7) 2 / 0 / 5 4.2% 
(5134/120852) 
c.7235G>A,  
p.S2412N 
(rs146309392) 
R1352 (1/7) 1 / 0 / 6 0.08% 
(77/96878) 
c.9790A>G,  
p.I3264V 
(rs139500146) 
R1256 (1/5) 1 / 0 / 4 1.08% 
(1297/120388) 
c.9766C>T,  
p.H3256Y 
(rs2291827) 
R1256 (2/5) 2 / 0 / 3 17.3% 
(20740/120026) 
c.8929C>T, 
p.R2977W 
(rs114851469) 
R1256 (2/5) 2 / 0 / 3 1.10% 
(1068/97498) 
c.6114C>G,  
p.I2038M 
(rs116788687) 
R1256 (1/5) 1 / 0 / 4 1.76% 
(2061/117092) 
c.4508C>T,  
p.A1503V 
(rs897471) 
R1352 (7/7) 
 R1256 (5/5) 
R1352: 0 / 7 / 0 
R1256: 0 / 5 / 0 
74.6% 
(68707/92062) 
c.2294A>C,  
p.N765S 
(rs989994) 
R1352 (7/7)  
R1256 (5/5) 
R1352: 0 / 7 / 0 
R1256: 0 / 5 / 0 
*98.11%  
(119030/121326) 
c.1912A>G,  
p.M638V 
(rs1874792) 
R1352 (7/7) 
R1256 (5/5) 
R1352: 0 / 7 / 0 
R1256: 0 / 5 / 0 
*99.3%  
(96055/96720) 
JDP2 c.37A>G, 
p.T13A 
(rs3625) 
R1256 (5/5) 5 / 0 / 0  53.0% 
(60318/113860) 
 
 
In the fourth column, the values in brackets indicate how many affected individuals have each 
variant (out of a possible five exomes in R1256, and seven exomes in R1352).  
 
*For rs6034867, rs989994, and rs1874792, the reference assembly contains the very rare minor 
allele at these loci, which was then labeled as the reference allele. As a result, the MAF values at 
these sites are extremely high in the general population. 
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thesis. As more association studies are published, the list of IA candidate genes will be 
updated.   
3.2.2 Data Summary Following Filtering of Whole Exome Variants   
After searching for variants in genes previously connected to IA, the direction of 
my project was steered toward novel genetic factors for IA predisposition within the 
whole exome. The step-wise implementation of the filtering strategy outlined in Figure 
10 significantly reduced the number of variants for each family, providing a more 
manageable dataset. The number of variants remaining after each step is summarized in 
Table 11.  
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 3.2.3 High Impact Variants: Family R1352  
 As expected, few high impact variants passed the selected filters used in my 
study. Variants categorized as “high impact” have a greater predicted effect on DNA 
sequence and overall protein assembly. For family R1352, a single variant remained that 
was present in 6/7 exomes at a read depth above 10, was detected in fewer than 1% of 
internal exome controls from MUGQIC, and had a MAF less than 1% in public variant 
databases. This variant in the C4orf6 gene results in the loss of the start codon, and has 
been previously reported in dbSNP under the identification number rs144117694 (Table 
12).  
 3.2.4 Moderate Impact Variants: Family R1352 
Five moderate impact variants remained in the dataset following filtering in 
R1352. Four of these variants were classified as missense, and the fifth was determined to 
be an inframe insertion (Table 13). Previously reported variants in ATP1A4, c.1798C>T, 
and GIGYF2, c.3494A>G, were present in 6/7 exomes. Additionally, the RP1L1 variant 
c.202C>T was detected in 6 exomes, and appears to be novel in this family. The MUC16 
variant c.40588G>A and the HSPBP1 insertion c.78_79insGGCGGCGGA were called in 
all 7 exomes, and were not previously reported in variant databases. All 5 of these 
variants required further consideration through Sanger sequencing validation.  
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Table 12. High impact variant in family R1352 that passed filtering steps. 
 
 
 
Table 13. Moderate impact variants in family R1352 that passed filtering steps. 
 
 
Column 5 of each table lists the number of exomes from family R1352 that were heterozygous 
(Het) for each given variant, followed by how many were homozygous (Hom) for the minor 
allele, and the number that were homozygous for the reference allele. For the MUGQIC MAF 
values, percentages are given based on 848 control exomes. For ExAC Browser MAF values, the 
fractions in brackets indicate the number of minor alleles in the dataset over the number of 
available sequenced alleles for this locus. 
 
Gene Chr. 
Position 
Status in 
dbSNP (rs#) 
Variant 
Details  
 
# Het / # Hom 
for Minor Allele 
/ # Hom for 
Reference Allele  
MAF in 
MUGQIC 
Controls  
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
C4orf6 4p16.2 Reported 
(rs144117694) 
c.1A>G;  
p.M1V 
Start-lost  
6 / 0 / 1 0%  
(0/848) 
0% 
(0/21384) 
Gene Chr. 
Position 
Status in 
dbSNP (rs#) 
Variant  
Details  
 
# Het / # Hom 
for Minor 
Allele / # Hom 
for Reference 
Allele 
MAF in 
MUGQIC 
Controls  
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
ATP1A4 1q23.2 Reported 
(rs142338502) 
c.1798C>T; 
p.P600S 
Missense 
5 / 1 / 1 0.59% 
(5/848) 
0.2002% 
(246/122948) 
GIGYF2 2q37.1 Reported 
(rs72554081) 
c.3494A>G;  
p.H1165R 
Missense 
6 / 0 / 1 0.59% 
(5/848) 
0.1586% 
(195/122946) 
RP1L1 8p23.1 Unreported c.202C>T; 
 p.L68F 
Missense 
6 / 0 / 1 0% 
 (0/848) 
N/A 
MUC16 19p13.2 Unreported c.40588G>A;  
p.G13530S 
Missense 
7 / 0 / 0 0%  
(0/848) 
N/A 
HSPBP1 19q13.42 Unreported c.78_79insGGCGGCGGA; 
p.G25_G26insAAD 
Inframe Insertion 
7 / 0 / 0 0.12% 
(1/848) 
N/A 
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 3.2.5 Low Impact Variants: Family R1352   
 In family R1352, 5 synonymous variants remained after filtering (Table 14). 
Three of these synonymous changes are in the same gene – MUC16. This gene was 
previously mentioned, as a missense variant in MUC16, c.40588G>A, also passed 
filtering. One of the synonymous MUC16 variants was previously reported in dbSNP, but 
was detected at an extremely low frequency in the ExAC Browser (0.000828%). The 
other two variants were found in all 7 exomes, and are apparently novel. Additionally, 
synonymous changes in COL6A3, c.702C>T, and APBB2, c.231G>A passed the filtering 
strategy. Both variants were called as heterozygous in 6/7 exomes, and were detected at 
low minor allele frequencies in exome control populations.  
 
 
 
 
 
 
 
 
 
 
 
 
 82 
 
Table 14. Low impact variants that passed filtering strategy in family R1352. 
 
Gene  Chr. 
Position 
Status in 
dbSNP (rs #) 
Variant 
Details 
# Het / # Hom 
for Minor Allele 
/ # Hom for 
Reference Allele  
MAF in 
MUGQIC 
controls 
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
COL6A3 2q37 rs142876356 c.702C>T 
p.L234 
6 / 0 / 1 0.12% 
(1/848) 
0.00505% 
(6/118902) 
APBB2 4p13 rs116718314 c.231G>A 
p.A77 
6 / 0 / 1 0.24% 
(2/848) 
0.1441% 
(174/120764) 
MUC16 19p13.2 rs111468097 c.41742C>A 
p.P13914 
6 / 0 / 1 0%  
(0/848) 
0.000828% 
(1/120766) 
Unreported c.40587T>C 
p.S13529 
7 / 0 / 0 0%  
(0/848) 
N/A 
Unreported c.37254G>A 
p.R12418 
7 / 0 / 0 0%  
(0/848) 
N/A 
 
Abbreviations: Het = heterozygous, Hom = homozygous  
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 3.2.6 High Impact Variants: Family R1256  
Two high impact variants passed the implemented filtering strategy in R1256 
(Table 15). A previously reported splice-site donor in the OCIAD1 gene was detected, as 
well as an unreported single-base deletion in CCDC3, leading to a frameshift. Both 
variants were detected in 4/5 exomes from the family and are heterozygous.  
 3.2.7 Moderate Impact Variants: Family R1256 
 Following the application of my initial filtering criteria, 66 moderate impact 
variants still remained for family R1256. To reduce this list of candidates to a more 
manageable number, I uploaded the list of 66 variants to the online Database for 
Annotation, Visualization and Integrated Discovery (DAVID) program, to determine 
whether any of these genes had functional relevance to IA pathogenesis (Huang da, 
Sherman, & Lempicki, 2009a; Huang da, Sherman, & Lempicki, 2009b). DAVID 
provides gene ontology and pathway keywords to annotate gene lists. Results of this 
endeavor were inconclusive, as no gene was a clear functional candidate for IA 
pathophysiology. Next, I decided to focus on variants that were found in all 5 exomes, 
and had not been previously reported with an identification number in dbSNP. This 
elimination step involves the assumption that there are no phenocopies among these 5 
sequenced individuals, and that any variants of interest are novel. This reduced the list of 
candidate variants to 15 (Table 16).  In this list of 15, the MUC16 and HSPBP1 variants 
previously reported in family R1352 were present.  
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Table 15. High impact variants in family R1256 that passed filtering steps. 
 
Abbreviations: Het = heterozygous, Hom = homozygous 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Chr. 
Position 
Status in 
dbSNP (rs#) 
Variant Details  
 
# Het / # Hom 
for Minor Allele 
/ # Hom for 
Reference Allele 
MAF in 
MUGQIC 
Controls 
(/848)  
MAF in 
ExAC 
Browser 
(/alleles) 
OCIAD1 4p11 Reported  
(rs144048911) 
c.-6+1G>A 
Splice Site Donor  
4 / 0 / 1 0% 
 (0/848) 
0.02851% 
(5/17538) 
CCDC3 10p13 Unreported c.425delA; 
p.Tyr267ThrfsTer21 
Frameshift 
4 / 0 / 1 0.35% 
(3/848) 
0.2677% 
(290/108350) 
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Table 16. Moderate impact variants in family R1256 that passed filtering criteria, 
were detected in 5/5 exomes, and were unreported in dbSNP. 
 
Gene Chr. 
Position 
Variant Details  
 
# Het / # Hom 
for Minor Allele 
/ # Hom for 
Reference Allele 
MAF in 
MUGQIC 
Controls 
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
POU3F1 1p34.1 c.82_84delGCG; 
p.A28del 
Inframe Deletion 
 5 / 0 / 0 0.94% 
(8/848) 
N/A 
MUC4 3q29 c.7165G>A;  
p.D2389N 
Missense 
5 / 0 / 0 0%  
(0/848) 
N/A 
MUC4 3q29 c.7166A>G; 
 p.D2389G 
Missense 
5 / 0 / 0 0%  
(0/848) 
N/A 
MUC4 3q29 c.7168G>C;  
p.A2390P 
Missense 
5 / 0 / 0 0% 
 (0/848) 
N/A 
MUC4 3q29 c.2989G>A;  
p.D997N 
Missense 
5 / 0 / 0 0.12% 
(1/848) 
N/A 
DSPP 4q22.1 c.2053_2054insGTAGC
AGTGACAGCAGCA; 
p.N685_S686insSSSDSS; 
Inframe Insertion 
3 / 2 / 0 0%  
(0/848) 
N/A 
MAML3 4q31.1 c.1468_1470delCAG; 
p.Q490del;  
Inframe Deletion 
0 / 5 / 0 0.83% 
(7/848) 
N/A 
DOPEY1 6q14.1 c.6902C>T;  
p.A2301V 
Missense 
5 / 0 / 0 0%  
(0/848) 
N/A 
CCDC3 10p13 c.217C>G;  
p.L73V 
Missense 
5 / 0 / 0 0.35% 
(3/848) 
N/A 
KNDC1 10q26.3 c.2686G>T;  
p.A896S 
Missense 
5 / 0 / 0 0% 
 (0/848) 
N/A 
MTG1 10q26.3 c.611C>T;  
p.P204L 
Missense 
5 / 0 / 0 0% 
 (0/848) 
N/A 
SPDYE4 17p13.1 c.103C>T;  
p.P35S 
Missense 
5 / 0 / 0 0.35% 
(3/848) 
N/A 
ZPBP2 17q12 c.622A>T;  
p.T208S 
5 / 0 / 0 0.12% 
(1/848) 
N/A 
 86 
Missense 
MUC16 19p13.2 c.40588G>A; 
p.G13530S 
Missense 
5 / 0 / 0 0% 
 (0/848) 
N/A 
HSPBP1 19q13.42 c.78_79insGGCGGCGG; 
p.G25_G26insAAD 
Inframe Insertion 
 5 / 0 / 0 0.12% 
(1/848)  
N/A 
 
Abbreviations: Het = heterozygous, Hom = homozygous 
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 Since MUC16 c.40588G>A and HSPBP1 c.78_79insGGCGGCGGA were present 
in all 5 exomes from family R1256 and all 7 exomes from R1352, these variants were of 
great interest. Both variants are also localized to Chr 19. In particular, the shared inframe 
insertion in HSPBP1 is notable, as 3 amino acids are inserted into the genomic sequence 
in affected individuals.  
 The additional 51 moderate impact variants for family R1256 are described in 
detail in Appendix D. Thirteen of these variants were detected in 5/5 exomes and were 
previously reported in dbSNP, 27 were detected in 4/5 exomes and were previously 
reported in dbSNP, and 11 were detected in 4/5 exomes and were unreported in dbSNP. 
Extensive prioritization and validation of top candidates from this list of 51 variants will 
be pursued at a later date.   
Within my variant lists, there was a high degree of disagreement between the 
predictive scores produced by in silico algorithms such as Polyphen2 and SIFT. This 
prevented me from further eliminating variants based on these scores alone. Functional 
predictive scores were noted for use in prioritizing variants later in the study, and for use 
as evidence to support candidate genes and their pathogenicity. Due to the manageable 
number of variants that passed my filtering strategy, I was able to avoid further filtering 
my data based on predicted functional relevance at this juncture. Therefore, all variants 
described in Tables 12, 13, 15 and 16 were Sanger sequenced to determine if they were 
true variants or false-positives. 
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 3.2.8 Low Impact Variants: Family R1256  
 My filtering strategy was also applied to the low impact variant list from family 
R1256, and 41 synonymous variants successfully passed filtering. The 11 variants that 
were detected in all 5 exomes from R1256 are highlighted in Table 17. The 30 additional 
synonymous variants present in 4/5 exomes are described in Appendix E.  The 3 MUC16 
variants from R1352 were also found in family R1256, along with 2 other unreported 
variants in this gene, c.39099C>T and c.390996C>A. This gene would not be prioritized 
in any hypothetical further analyses, due to the highly polymorphic nature of this locus.  
An unreported change in HLA-DRB1 would also be removed from further study, as it was 
called in an alternate haplotype of this Chr 6 region, and this gene is known to be a highly 
polymorphic “super SNP” gene in the general population (Ju et al., 2010). “Super SNP” 
genes are enriched with non-synonymous variation, and may not be relevant to IA 
pathogenesis. Ju et al. (2010) state that most of their classified “super SNP” genes are 
involved in sensory and immune function, such as olfactory receptor and HLA genes. 
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Table 17. Low impact variants that passed filtering strategy, and were detected in 
all 5 exomes from family R1256. 
 
Gene  Chr. 
Position 
Status in 
dbSNP (rs #) 
Variant 
Details 
# Het / # Hom for 
Minor Allele / # 
Hom for 
Reference Allele  
MAF in 
MUGQIC 
controls 
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
TNRC18 7p22.1 Unreported  c.3807C>T 
p.P1269 
5 / 0 / 0 0%  
(0/848)  
*0.008% 
(1/12503) 
OTOGL 12q21.31 rs145834039 c.3486C>T 
p.G1162 
3 / 2 / 0 0.35%  
(3/848) 
0.2827% 
(341/120626) 
PCDH9 13q21.32 rs146618643 c.60C>T 
p.S20 
4 / 1 / 0 0.35%  
(3/848) 
0.1431% 
(170/118834) 
FAM83G 
 
17p11.2 Unreported c.2208A>G 
p.P736 
5 / 0 / 0 0%  
(0/848) 
N/A 
GPR179 17q12 rs202228440 c.5868C>T 
p.S1956 
5 / 0 / 0 0.35%  
(3/848) 
0.07619% 
(92/120746) 
MUC16 19p13.2 rs111468097 c.41742C>A 
p.P13914 
5 / 0 / 0 0%  
(0/848) 
0.000828% 
(1/120766) 
Unreported c.40587T>C 
p.S13529 
5 / 0 / 0 
 
0%  
(0/848) 
N/A 
Unreported c.39099C>T 
p.S13033 
5 / 0 / 0 0%  
(0/848) 
N/A 
Unreported 
 
c.39096C>A 
p.G13032 
5 / 0 / 0 0%  
(0/848) 
N/A 
Unreported 
 
c.37254G>A 
p.R12418 
5 / 0 / 0 0%  
(0/848) 
N/A 
HLA-
DRB1 
+
6_ssto_ 
hap7 
Unreported  
p.R99 
0 / 5 / 0 0%  
(0/848) 
N/A 
 
Abbreviations: Het = heterozygous, Hom = homozygous 
 
*MAF was not reported in ExAC Browser, but was present in NHLBI Exome Variant Server.  
+
6_ssto_hap7 is an alternate haplotype for chromosome 6.  
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3.3 NextGene
®
 Results 
3.3.1 Family R1352 Variants  
Through the use of the Variant Comparison Tool (VCT), it was determined that 7 
homozygous missense and 51 heterozygous missense variants were shared by the 7 
exomes from family R1352 and were absent from control exomes IPF:Z37 and 
CRC:RD218. No high impact variants were detected with this tool, and all 7 homozygous 
missense variants had dbSNP MAF values above 15%.  There was no overlap between 
the list of heterozygous missense variants with my filtered MUGQIC data. Therefore, the 
MUC16 p.G13530S and HSPBP1 p.G25_G26insAAD variants were not detected through 
NextGene
®
. Functional annotation with GeneCards and DAVID did not yield any 
promising hits for IA-related keywords in this list of 51 variants. A list of keywords was 
generated containing words and phrases that appear frequently in descriptions of the IA 
phenotype and pathophysiology in published articles (Appendix F). To expand the scope 
of the data output and possibly find novel or rare variants not detected by the MUGQIC 
pipeline, I then used the VCT to compare the exomes of siblings Z1039, Z1040, Z1497 
and Z1508 to the 2 controls. Though the additional relatives share a phenotype (Z1507, 
Z1533, Z1651), they are more distantly related and could be phenocopies in this family. 
This was a generous filtering method, as variants shared by 4 or more exomes out of 7 are 
included in these results. The objective was to identify variants in functionally relevant 
genes that were omitted following stringent filtering.  
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3.3.2 Family R1352 Variants Shared by 4 Siblings   
 A total of 50 homozygous missense and 618 heterozygous missense variants were 
shared by Z1039, Z1040, Z1497 and Z1508, but were not found in the control exomes. 
By using the dbSNP MAF values provided by NextGene
®
, these values were reduced to 2 
homozygous and 141 heterozygous missense variations with an unreported MAF or value 
less than 1%. This significant drop shows the importance of considering allele frequency 
when searching for disease-related variants.  It is still highly likely that some of these 143 
variants are common, as many of the corresponding dbSNP MAF values were 
unreported, and would have to be imputed manually.  
 Within this list of 143 variants, the 3 remaining missense calls from Table 13 
were detected: ATP1A4 c.1798C>T, GIGYF2 c.3494A>G, and RP1L1 c.202C>T. Each of 
these variants was called in 6/7 exomes by NextGene
®
. ATP1A4 c.1798C>T and GIGYF2 
c.3494A>G were absent from individual Z1651, and RP1L1 c.202C>T was absent from 
Z1533, which matched the MUGQIC results. The successful replication of these calls 
provides increased confidence and evidence to support the bioinformatics pipeline used 
by MUGQIC. It is interesting to note that several variants called by NextGene
®
 were not 
actually discovered through MUGQIC variant calling. Discrepancy across different 
analysis pipelines is a known issue in NGS research, which can be partly ameliorated by 
using multiple pipelines to analyze raw exome reads.  
  Finally, the list of 143 variants was uploaded to DAVID to search for any genes 
with possible IA-related functionality. A rare variant in the COL6A3 gene, c.5610C>A, 
was highlighted, which has been previously reported in dbSNP (rs113153193). This 
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variant has a MAF of 0.128% in the ExAC Browser, as it has been detected in 
154/120,552 alleles. The COL6A3, collagen type 6 alpha 4, protein was noted in DAVID 
for its role in collagen biosynthesis and cell adhesion. This variant was found in 6/7 
exomes by NextGene
®
, but was not called by MUGQIC. A second gene of interest was 
recognized through DAVID, the adenylate cyclase 1 (brain) gene, ADCY1.  The ADCY1 
variant c.1837G>A was only called in the 4 siblings (4/7 exomes), and has been 
previously reported in dbSNP as rs752410249. In the ExAC Browser, this variant has a 
low MAF of 0.0033%, and has only been detected in 4/121412 alleles. Endothelin-
1/EDNRA signaling was identified as a pathway related to ADCY1 function in 
GeneCards and DAVID. Endothelin-1 is known to be involved in the dilation and 
constriction of blood vessels, and EDNRA has been previously identified as an IA 
candidate gene (Yasuno et al., 2011). ADCY1 may also be involved in brain development 
and regulatory processes in the central nervous system. This ADCY1 variant, c.1837G>A, 
was also not present in the MUGQIC variant lists. Validation of these variants will be 
pursued in the future.   
3.3.3 Family R1256 Variants  
In family R1256, 18 homozygous missense and 223 heterozygous missense 
variants were shared by the 5 exomes, and were not present in either control exome. The 
majority of the detected, shared variants have high MAF values reported in dbSNP, and 
are not of interest in this project. Two heterozygous nonsense variants were also shared 
by the 5 exomes and were absent in controls, though both were reported at high 
frequencies in dbSNP. Unfortunately, with this version of NextGene
®
, I was unable to 
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detect other high impact variant types including splice site and frameshift variants with 
accuracy. Therefore, the OCIAD1 and CCDC3 high impact variants detected by 
MUGQIC could not be replicated in this dataset. After reviewing the list of 241 missense 
variants, it was evident that there was a significant degree of overlap with my filtered 
variants that were called and annotated by MUGQIC.  From the list of 15 variants in 
Table 16, seven calls were replicated with NextGene
®
. These variants included MUC4 
c.2989G>A, DOPEY1 c.6902C>T, CCDC3 c.217C>G, KNDC1, c.2686G>T, MTG1 
c.611C>T, SPDYE4 c.103C>T, and ZPBP2 c.622A>T. It is possible that some of the 
remaining 8 variants were also called by NextGene
®
, but were excluded by the use of 2 
control exomes. Given that scenario, the NextGene
®
 software is effectively helping to 
eliminate variants that are generally common or are prevalent in the NL population.  
Across both families, there was a high degree of confirmation from NextGene
®
 to 
support my filtered variant lists. Therefore, it can be concluded that NextGene
®
 could be 
a helpful secondary analysis tool to provide additional evidence of variant discovery.  
 
3.4 Homozygous Variation in Siblings from Family R1352  
 
 As stated previously, the majority of variants that passed the filtering strategy 
were heterozygous in affected participants. However, there were several incidences 
where the classification of homozygosity and heterozygosity was split for a given variant. 
For example, R1256 family members Z1405, Z1441, and Z1448 were homozygous for a 
c.3704C>T missense variant in MYO18A, while Z929 and Z1406 were heterozygous. 
However, there were many homozygous variants present in each family that were not 
shared by all or most members. In family R1352, there was a large subset of variants that 
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were shared by the main group of siblings (Z1039, Z1040, Z1497, and Z1508). For many 
of these variants, there was a split between exomes that were homozygous and 
heterozygous for the minor allele. Given the strong evidence for familial predisposition to 
IA in R1352, and the lack of a strong candidate from my filtering methodology, it was 
determined that investigation into homozygous variation in these four siblings would be 
worthwhile.   
 Table 18 summarizes 14 variants that were shared by at least the 4 siblings  
(Z1039, Z1040, Z1497 and Z1508), were called as homozygous in at least 1 exome, and 
have a MAF value less than 5% in internal exome controls and the ExAC Browser. The 
5% cutoff was selected to see what effect increasing the MAF limit would have on the 
generated results. Almost all of the 14 variants had a MAF above 1%, which would have 
eliminated them from my previous filtering strategy. ATP1A4 c.1798C>T was previously 
analyzed, as it passed the original filtering strategy for this project. ZFPM1 
c.1334_1339delCTCCGG also passed initial filtering, but was not prioritized. At the 
onset of this project, the ZFPM1 variant was mis-classified by dbSNP and Ensembl as a 
common variant. The deletion was classified as a common variant, while the reference 
allele was classified as rare in public datasets. After discovering this discrepancy, this 
variant was highlighted as a site of interest, as it was shared by all exomes in both 
families R1256 and R1352. Sanger sequencing was completed to determine if this variant 
was a true positive.  
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Table 18. Variants shared by exomes Z1039, Z1040, Z1497 and Z1508 that are 
homozygous in at least one exome, and have a MAF less than 5%.  
 
Gene  Chr. 
Position 
Status in 
dbSNP       
(rs #) 
Variant 
Details 
# Het / # Hom for 
Minor Allele / # Hom 
for Reference Allele  
MAF in 
MUGQIC 
controls 
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
*ATP1A4 1q23.2 rs142338502 
 
 
c.1798C>T,  
p.P600S 
5 
(Z1508,1497,1039,1533,1040) 
 / 1 (Z1507) / 1 (Z1651) 
0.59% 
(5/848) 
0.2002%  
(246/122948) 
PTPRC 1q31.3 
 
 
rs41269905 
 
 
c.367G>C, 
p.D123H 
4 (Z1533, 1651, 1508, 1039) 
 / 1 (1507)  / 2 (Z1040, 
Z1497) 
2.48% 
(21/848) 
1.39%  
(1684/121386) 
rs2230606 
 
 
c.403A>C, 
p.I135L 
4 (Z1533, 1651, 1508, 1039) 
 / 1 (1507) / 2 (Z1040, 1497)  
2.83% 
(24/848) 
1.59% 
(1929/121330) 
LY75 2q24.2 rs78446341 
 
c.3740C>T, 
p.P1247L 
4 (Z1497, 1507, 1533, 1039) 
/ 2 (Z1508, 1040) / 1 (Z1651) 
3.77%  
(32/848) 
1.99%  
(2417/121340) 
STX2 12q24.33 rs137928907 
 
c.94T>G, 
p.F32V 
3 (Z1507, 1039, 1497)  
/ 2 (Z1508, 1040) / 2 (Z1533, 
1651) 
4.83%  
(41/848) 
1.45% 
(1759/121032) 
SEZ6L2 16p11.2 rs113753753 
 
c.1210G>A, 
p.D404N 
4 (Z1533, 1039, 1497, 1508) 
/ 1 (Z1507) / 2 (Z1040, 1651)  
3.66%  
(31/848) 
1.69% 
(2001/118422) 
*ZFPM1 16q24.2 rs149145771 c.1334_1339
delCTCTGG 
p.L446_A44
7del 
Inframe 
Deletion 
0 / 7 / 0 0.35%  
(3/848) 
0% 
(0/118) 
MUC16 19p13.2 
 
rs183524392 
 
c.9359C>A, 
p.T3120N 
5 (Z1651, 1508, 1497, 1039, 
1533) 
 / 1 (Z1040) / 1 (Z1507) 
1.77%  
(15/848) 
0.91%  
(1098/120754) 
 
Abbreviations: Het = heterozygous, Hom = homozygous 
 
*These variants also passed the original filtering strategy from Figure 11.  
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3.5 Validation and Segregation Analysis  
 
 Following validation by Sanger sequencing, it was discovered that there were no 
shared high or moderate impact variants between the 2 families in our study. Sanger 
sequencing of MUC16 c.40588G>A and HSPBP1 c.78_79insGGCGGCGGA revealed 
that these genetic variants were not actually present in any of the 7 family members from 
R1352, nor the 5 affected members from R1256. The MUC16 and HSPBP1 variants were 
classified as false-positive calls, which is not uncommon in exome sequencing studies. 
This result was also foreshadowed by their absence from the NextGene variant reports.  
 As well, the 2 families did not share any prioritized variants in the same gene. 
This is consistent with genetic heterogeneity in familial IA. It is possible that these 2 
families have completely different loci that are contributing to IA risk. The following 
sub-sections provide a summary of the Sanger sequencing results for exome-sequenced 
individuals and for any additional affected relatives.   
 3.5.1 High Impact Variants: Family R1352 
 Sanger sequencing confirmed the presence of the C4orf6 variant in 6 of 7 exomes 
(Table 19). I was able to sequence this region in an additional affected family member, 
Z1496, who is the father of several study participants (Z1039, Z1040, Z1497, Z1508). 
The C4orf6 variant was not detected in this individual, though sequencing 
chromatograms for this DNA sample were distorted and difficult to interpret with 
certainty. The DNA extraction process did not yield high quality product for study 
participant Z1496 and his spouse, Z1495. Sequencing of these samples produces poor 
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sequence quality and often, failed PCR. Therefore, Z1496 was not used in the segregation 
analysis of moderate impact variants from this family.  
 At the onset of this study, C4orf6, also known as Chromosome 4 open reading 
frame 6, was reported as encoding an uncharacterized protein product. More recently, 
C4orf6 has been categorized as a long intergenic non-protein coding RNA gene in 
GeneCards. The lack of functional information associated with this gene makes it 
difficult to confidently create a connection to the pathophysiology of IA. In order to get a 
better idea of the potential involvement of c.1A>G in IA development, DNA from a 
selection of unaffected relatives was Sanger sequenced in R1352 (Figure 12). This test 
group consisted of 14 unaffected individuals. These relatives were considered to be 
informative and relevant, due to their presence in the 2 generations of the pedigree that 
contain all known affected individuals. Clinical information and DNA are available for 
family members in a younger generation, which is not shown in the condensed pedigree 
for R1352. Individuals in this generation are currently outside of the normal age range for 
IA development, as IA is a late-onset disorder. The current age range of these individuals 
is 14-36, with a mean age of 26.9 in the year 2015. It is quite possible that some of these 
younger relatives will develop IA in their lifetime, and variant analysis at this point 
would not contribute greatly toward our understanding of IA mode of inheritance and 
etiology.  
 It was determined that 5/14 unaffected relatives were carriers of this variant. 
Seven asymptomatic relatives did not have the variant, as they were homozygous for the 
reference allele at this locus. Individuals Z1537 and Z1509, who have been diagnosed 
with abdominal aortic aneurysm, also did not have the C4orf6 variant. The use of in silico 
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predictive tools for this site provided conflicting results. This variant had a reported 
GERP score of 0.225, which predicts that the methionine at this site is not highly 
conserved. C4orf6 c.1A>G was predicted to be benign by Polyphen2, but was predicted 
to be deleterious by SIFT, with a score of 0.  
 Though C4orf6 c.1A>G exhibits incomplete segregation in this family, it remains 
the top candidate due to its classification as high impact. Therefore, this variant was 
chosen to be Sanger sequenced in a cohort of population controls from Newfoundland 
and Labrador. Sanger sequencing of the C4orf6 c.1A>G variant was completed in 100 
randomly selected control samples from the Newfoundland and Labrador Colorectal 
Cancer Registry (NFCCR) cohort. Analysis of the DNA sequence chromatograms 
showed that this variant was not present in any member of the control set (Figure 13). 
Therefore, it is assumed that the C4orf6 c.1A>G variant is not common in the NL 
population.  
 3.5.2 Moderate Impact Variants: Family R1352 
Validation by Sanger sequencing was successful for the ATP1A4, GIGYF2 and 
RP1L1 missense variants (Table 20). It was confirmed that each of these variants was 
present in 6/7 exomes from family R1352. In order to assess the predicted pathogenicity 
of these three variants, the scores from GERP, Polyphen2 and SIFT were recorded and 
evaluated. ATP1A4 c.1798C>T had a significant GERP score of 4.19, and was predicted 
to be damaging by both Polyphen2 and SIFT. GIGYF2 c.3494A>G had a highly 
conserved GERP score of 5.43 out of a possible 6. It was predicted to be damaging by 
Polyphen2, but benign by SIFT, with a score of 0.19 out of 1. RP1L1 c.202C>T yielded 
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similar results, with a conserved GERP score of 4.19. This variant was also predicted as 
damaging by both Polyphen2 and SIFT. To assess their relevance to IA, a PubMed search 
was conducted for all three genes. Other databases including UniProt, OMIM and 
GeneCards were also explored to determine gene function.  
ATP1A4 encodes the sodium/potassium-transporting ATPase subunit alpha-4 
protein, which is involved in the creation of an electrochemical gradient across the 
plasma membrane. This protein is also known to have a role in sperm motility. RP1L1, or 
retinitis pigmentosa 1-like 1, has a role to play in photoreceptor cell differentiation in the 
human eye. This gene has been previously associated with occult macular dystrophy in 
Japanese families (Akahori et al., 2010). Finally, GIGYF2 encodes the GRB10- 
interacting GYF protein 2. This protein has been categorized by gene ontology terms 
including “negative regulation of translation” and “post-embryonic development”, and 
has fairly ubiquitous expression throughout the body. Heterozygous variants in the 
GIGYF2 gene have been associated with autosomal dominant Parkinson disease type 11, 
which is a neuromuscular disorder (Lautier et al., 2008). This gene is also believed to 
play a role in tyrosine kinase receptor signaling, which is essential to the regulation of 
cellular processes in the body.   
In order to distinguish between these 3 variants, a number of unaffected family 
members were Sanger sequenced. Neither variant was absent from all unaffected 
relatives, though incomplete penetrance remains a distinct possibility. ATP1A4 
c.1798C>T was present in 4/11 unaffected relatives, including one family member with 
AAA (Figure 14). However, the other family member with AAA did not have the variant. 
GIGYF2 c.3494A>G was present in 5/14 unaffected relatives, including 1 individual with 
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AAA (Figure 15). Finally, RP1L1 c.202C>T was present in 4/13 unaffected relatives, but 
was absent from both family members with AAA (Figure 16). Therefore, the results of 
unaffected Sanger sequencing did not provide a clear visualization of what moderate 
impact variant(s) should be prioritized. Functionally, GIGYF2 appeared to have the most 
potential out of these three genes, and was sequenced in 100 population controls from the 
NFCCR cohort. This variant was absent from all 100 controls, which suggests that this 
substitution is not common in the NL population (Figure 17).  
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Table 19. Sanger sequencing results for filtered high impact variants from family 
R1352. 
 
 
 
Table 20. Sanger sequencing results for filtered moderate impact variants from 
family R1352. 
 
Δ 
WES results were consistent with results obtained by Sanger sequencing. 
 
 
 
 
 
 
 
 
 
Gene Variant 
Details 
# of Sequenced 
Affected 
Individuals with 
Variant
Δ
 
Affected 
Individuals with 
Variant 
Affected 
Individuals 
without Variant 
C4orf6 c.1A>G; 
p.M1V 
Start-lost 
6/8 Z1039, Z1040, 
Z1497, Z1507, 
Z1508, Z1651 
Z1533, Z1496 
Gene Variant 
Details 
# of Sequenced 
Affected 
Individuals with 
Variant
Δ
 
Affected 
Individuals with 
Variant 
Affected 
Individuals 
without 
Variant 
ATP1A4 c.1798C>T; 
p.P600S 
Missense 
6/7 Z1039, Z1040, 
Z1497, Z1507 
(homozygous), 
Z1508, Z1533 
Z1651 
GIGYF2 c.3494A>G; 
p.H1165R 
Missense 
6/7 Z1039, Z1040, 
Z1497, Z1507, 
Z1508, Z1533 
Z1651 
RP1L1 c.202C>T; 
p.L68F 
Missense 
6/7 Z1039, Z1040, 
Z1497, Z1507, 
Z1508, Z1651 
Z1533  
 102 
 
                  
F
ig
u
re 1
2
.  S
eg
reg
a
tio
n
 o
f C
4
o
rf6
, c.1
A
>
G
 in
 fa
m
ily
 R
1
3
5
2
.  
 
D
N
A
 ex
tractio
n
 w
as co
m
p
leted
 fo
r in
d
iv
id
u
als w
ith
 a Z
 id
en
tificatio
n
 n
u
m
b
er. IA
 affectio
n
 statu
s is in
d
icated
. F
o
r 
u
n
affected
 in
d
iv
id
u
als, th
e d
ate o
f th
eir last k
n
o
w
n
 n
eg
ativ
e C
T
 scan
 is in
d
icated
 w
h
ere av
ailab
le.  
 
 103 
 
(A) 
 
 
(B) 
 
 
 
 
 
Figure 13. Chromatogram of Sanger sequencing results for C4orf6 c.1A>G. 
 
The top image (A) shows confirmation of the heterozygous start-lost variant in an affected 
member of R1352. The bottom image (B) shows results for a control individual who is 
homozygous for the reference allele.  
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(A) 
 
(B) 
 
Figure 17. Chromatogram of Sanger sequencing results for GIGYF2 c.3494A>G.  
 
The top image (A) shows confirmation of the heterozygous variant in an affected member of 
R1352, in both the forward and reverse sequences. The bottom image (B) shows the absence of a 
variant at this position in an unaffected control sample.  
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 3.5.3 Homozygous ZFPM1 Variant: Family R1352  
Sanger sequencing of the ZFPM1 c.1334_1339delCTCCGG variant was 
unsuccessful, as PCR ventures did not yield any product.  Based on previous experience, 
it is possible that this deletion was a false positive, as it was shared by all exomes in our 
cohort. As well, the ZFPM1 locus was only covered by 118 alleles in the ExAC browser. 
On the ExAC website, a warning is issued at the top of some entries, to indicate that a site 
is covered by less than 80% of the individuals in the database. This warning states that 
these entries may be low quality sites. Though none of the 14 variants in Table 18 is a 
clear functional candidate for IA, these lists show that different methods of thinking 
about exome data and filtering in the context of complex disease should be explored. 
 3.5.4 High Impact Variants: Family R1256  
Sanger sequencing confirmed that the CCDC3 and OCIAD1 high impact variants 
were present in 6 of 7 exomes (Appendix G; Table 21). CCDC3 encodes the coiled-coil 
domain containing 3 protein. Azad et al. (2014) determined that CCDC3 was expressed 
in adipose tissues and endothelial cells, including those in the aortic wall. They were able 
to determine that CCDC3 is involved in the repression of TNF-α induced VCAM-1 
(vascular cell adhesion molecule 1) expression. TNF-α activity is believed to activate 
nuclear factor kB (NF-kB) signaling, and induce an inflammatory response in endothelial 
cells. Therefore, the secretory protein CCDC3 has a possible role in the regulation of 
inflammation in this pathway. OCIAD1 encodes the ovarian carcinoma immunoreactive 
antigen domain-containing protein 1. This protein has wide expression throughout the 
body, and one of its isoforms is strictly expressed in the brain and nervous system (Luo, 
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Soosaipillai, & Diamandis, 2001). Functional annotation for this gene is limited, though it 
has been reported as over-expressed in ovarian cancer tissues through the use of a mouse 
model (Sengupta, Michener, Escobar, Belinson, & Ganapathi, 2008).  
Additional affected members of R1256 were then sequenced, to see how these 
variants segregate with the disease throughout the entire affected family. CCDC3 
c.425delA was absent from 5 affected family members, and OCIAD1 c.-6+1G>A was 
absent from 2 individuals in total (Table 21). The transmission of these variants is shown 
on the R1256 pedigree in Appendix G. The absence of these variants from multiple 
affected family members meant that they were not prioritized for further study at this 
time.  
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Table 21. Sanger sequencing results for filtered high impact variants from family 
R1256. 
 
Δ
WES results were consistent with results obtained by Sanger sequencing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Variant Details # of Sequenced 
Affected 
Individuals with 
Variant
Δ
 
Affected 
Individuals with 
Variant 
Affected 
Individuals 
without 
Variant 
OCIAD1 c.-6+1G>A 
Splice Site Donor 
 
6/8 Z929, Z1405, 
Z1406, Z1448, 
Z1459, Z1501 
Z1390, Z1441  
CCDC3 
 
c.425delA; 
p.Tyr267ThrfsTer21 
Frameshift 
 
5/10 Z1390, Z1405, 
Z1406, Z1441, 
Z1448 
Z929, Z1013, 
Z1459, Z1501, 
Z1471 
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3.5.5 Moderate Impact Variants: Family R1256 
 Sanger sequencing of the 15 novel, shared moderate impact variants revealed that 
the MUC16 p.G13530S and HSPBP1 p.G25_G26insAAD variants were false-positive 
calls, as discovered in R1352.  The MUC4 c.2989G>A variant was also classified as a 
false-positive, as it was not detected in exomes Z1405, Z1406 or Z1441. The sequencing 
chromatograms for Z929 and Z1448 were messy, and re-sequencing yielded similar 
results. A cluster of three variants (p.D2389N; p.D2389G; and p.A2390P) in MUC4 were 
not validated, due to the highly polymorphic nature of this region. Acceptable primers 
could not be designed for this site with the Primer3 program, to meet the minimal 
accepted standards for successful use in PCR. Regardless, this area of MUC4 contains a 
number of deletions, and many repetitive sequences, which would cause non-specific 
binding of any primers. Sanger sequencing of the DSPP, POU3F1 and MAML3 variants 
was also unsuccessful. Despite the use of various thermocycler protocols, and different 
attempts at primer optimization, PCR did not yield any product for these sites. None of 
these variants were confirmed by NextGene
®
, and thus they may be false-positive calls as 
well.  
Validation of the 6 remaining variants was successful, and all 6 had been 
confirmed through NextGene
®
. Following validation, additional affected relatives were 
sequenced for each variant. DOPEY1 c.6902C>T, CCDC3 c.217C>G, and KNDC1 
c.2686G>T were all confirmed in 7/10 affected individuals in R1256 (Table 22). MTG1 
c.611C>T was only confirmed in 3/10 individuals, which may mean that read depth or 
overall sequencing quality was relatively low for exomes Z929 and Z1448 at this site of 
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the genome. An additional affected family member, Z1522, was only successfully 
sequenced for 2 variants, due to low DNA sample quality. This increased the pool of 
affected family members to 11. Thus, ZPBP2 c.622A>T was confirmed in 8/11 affected 
family members. Finally, SPDYE4 c.103C>T was validated in 10/11 affected members of 
R1256. This variant had the highest degree of segregation with IA, compared to the other 
5 candidates. As a result, a cohort of unaffected relatives was Sanger sequenced for the 
SPDYE4 c.103C>T site (Figure 18). Pedigrees depicting the segregation of the other 
R1256 validated variants are located in Appendix G. A chart outlining the gene function 
and predictive scores for these 5 variants is also located in Appendix H.  
SPDYE4 c.103C>T was present in 8/14 unaffected relatives from R1256. As 
stated previously, it is possible that some of these family members may develop IA in 
their lifetime, or that incomplete penetrance is a factor. The dates at which these 
individuals received their last CT scan or MRI is indicated on the pedigree, and some 
individuals have not been screened in almost 10 years. It is possible that follow-up 
appointments could change the overall look of this pedigree, and result in the diagnosis 
and treatment of additional affected individuals. The SPDYE4 gene encodes the Speedy 
protein E, and was classified by the gene ontology term “regulation of protein kinase 
activity”. A PubMed search for this gene revealed no results, as it has not been previously 
connected to any human disease.  
 With regards to predictive scores, SPDYE4 c.103C>T has a GERP score of 2.65, 
which is just below the cut-off for significant evolutionary conservation. It was predicted 
as benign by Polyphen2, but damaging by SIFT (0.02). The disagreement between these 
scores does not provide us with a clear indication of this variant’s relevance to IA 
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pathogenesis. Further functional analysis would be necessary to better understand the role 
of SPDYE4 in familial IA.  
 Consequently, Sanger sequencing of the SPDYE4 c.103C>T variant was 
completed in 100 randomly selected control samples from the NFCCR cohort. The 
variant was not present in any of these individuals, as demonstrated by the example 
chromatogram in Figure 19. The absence of SPDYE4 c.103C>T from NL controls 
suggests that this variant is not found in the local population at an increased frequency 
compared to global datasets. This variant is a promising top candidate in family R1256, 
based on my stringent filtering criteria. It is also possible that an additional candidate 
may be present among the other moderate impact variants that are highlighted in 
Appendix D. In the coming stages of this study, in silico predictive programs may be 
used to prioritize these variants, along with functional annotation from DAVID and other 
avenues.  
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Table 22. Sanger sequencing results for filtered moderate impact variants from 
family R1256. 
 
Gene Variant 
Details 
# of Sequenced 
Affected 
Individuals with 
Variant
Δ
  
Affected 
Individuals with 
Variant 
Affected 
Individuals 
without Variant 
DOPEY1 c.6902C>T; 
p.A2301V 
Missense 
7/10 Z929, Z1390, 
Z1405, Z1406, 
Z1441, Z1448, 
Z1459  
Z1013, Z1471, 
Z1501 
CCDC3 c.217C>G; 
p.L73V 
Missense 
7/10 Z929, Z1390, 
Z1405, Z1406, 
Z1441, Z1448, 
Z1471 
Z1013, Z1459, 
Z1501 
KNDC1 c.2686G>T; 
p.A896S 
Missense 
7/10 Z929, Z1013, 
Z1405, Z1406, 
Z1441, Z1448, 
Z1471 
Z1390, Z1459, 
Z1501 
MTG1 c.611C>T; 
p.P204L 
Missense 
3/10 Z929, Z1013, 
Z1448 
Z1390, Z1405, 
Z1406, Z1441, 
Z1459, Z1471, 
Z1501  
SPDYE4 c.103C>T; 
p.P35S 
Missense 
10/11 Z929, Z1013, 
Z1390, Z1405, 
Z1406, Z1441, 
Z1448, Z1459, 
Z1471, Z1501 
Z1522 
ZPBP2 c.622A>T; 
p.T208S 
Missense 
8/11 Z929, Z1013, 
Z1390, Z1405, 
Z1406, Z1441, 
Z1448, Z1501   
Z1459, Z1471, 
Z1522 
 
Δ
WES results were consistent with results obtained by Sanger sequencing.  
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(A) 
 
(B) 
 
Figure 19. Chromatogram of Sanger sequencing results for SPDYE4 c.103C>T.                         
 
The top image (A) shows confirmation of the heterozygous variant in an affected member of 
R1256, in both the forward and reverse sequences. Image (B) shows the absence of the variant in 
a population control individual who is homozygous for the reference allele.   
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 3.5.6 Comparison to Farlow et al., 2015 Study  
 In reference to section 2.7, I compared my lists of filtered variants to those 
summarized in a recent study by Farlow et al. (2015). They identified 68 candidate 
variants from an exome sequencing study of 7 international families affected by non-
syndromic IA. IA cases were diagnosed by surgical reports, autopsy, or non-invasive 
imaging. A group of 3 neurologists reviewed the medical records to ensure that all 
criteria were met for inclusion of these individuals in the study. None of these 68 variants 
overlapped with my filtered moderate and high impact lists. However, the gene TRPA1 
appeared in both their list of candidates, and my list of filtered moderate impact variants 
for family R1256. Farlow et al. (2015) reported a missense variant c.2059A>T in TRPA1, 
which encodes transient receptor potential cation channel, subfamily A, member 1 
protein. This variant was detected in only 1 of their multiplex families, and segregated 
with IA incidence. TRPA1 c.2059A>T also appears to be novel, as it has an allele 
frequency of 0% in 1000 Genomes and the NHLBI Exome Variant Server.  
In my study, the missense variant c.1309G>A was detected in 4/5 exomes, as it 
was absent from sample Z1441. This missense change is predicted to be rare or novel, as 
it has not been previously reported in dbSNP or other exome variant databases including 
the ExAC Browser. As this gene was the only commonality between the Familial 
Intracranial Aneurysm study and our cohort, I completed validation via Sanger 
sequencing to confirm the presence of the variant. The variant was indeed present in 4/5 
family members, and thus additional affected members were tested for segregation. 
Following segregation analysis, TRPA1 c.1309G>A was found in 6/10 affected family 
 118 
members that were successfully sequenced (Figure 20). The incomplete segregation of 
this variant resulted in its elimination from further analysis at this time. 
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3.6 Excluded Moderate Impact Variants in Family R1256  
 
  Following the main collection of results, it was determined that further 
exploration of the excluded moderate impact variants in family R1256 was a necessary 
endeavor. The initial list of 66 filtered, moderate impact variants in R1256 was 
previously reduced to novel variants that were found in 5/5 exomes. Of the remaining 51 
variants (Appendix D), several could be prioritized based on MAF alone. Of the 13 that 
were detected in 5/5 exomes, and previously reported in dbSNP, a variant in the MYO18A 
gene stands out.  The c.3704C>T variant, rs777985641, was called as heterozygous in 2 
exomes, and homozygous in 3 exomes. This variant has an extremely low MAF of 
0.000828% in the ExAC browser, and was only detected in 1/120,720 sequenced alleles. 
It was determined that Sanger sequencing was worth pursuing to validate this variant. 
Homozygosity of this variant was confirmed in individuals Z1405, Z1441, and Z1448. 
Family members Z1406 and Z929 were also confirmed to be heterozygous at this site. 
Additional affected relatives were also successfully sequenced. Three other relatives 
(Z1013, Z1390 and Z1501) were heterozygous for MYO18A c.3704C>T, and three did 
not have the variant (Z1459, Z1471 and Z1522). The confirmation of this substitution in 
8/11 affected relatives is consistent with the results obtained for ZPBP2 c.622C>T.  
 Of the 38 variants that were detected in 4/5 exomes, several were similarly rare in 
the ExAC browser. In family R1256, it was previously reported that 3 markers in a 22 cM 
region on chromosome 14 were suggestive of linkage, and the Chr 14q23-31 region has 
been linked to familial IA in other publications (Ozturk et al., 2006; Mineharu et al., 
2008). In the list of 38, there were 2 variants on Chromosome 14 that had been previously 
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reported in dbSNP (Appendix D). A missense variant in OR11H4, c.55G>A, was 
identified, which is located at chromosomal position 14q11.2. This variant has a MAF of 
0.1199% in the ExAC browser. Secondly, a missense variant in LTBP2, c.2657C>A, 
passed the initial filtering strategy. This variant has a MAF of 0.07206% in ExAC, and 
had been previously detected in 70/97,140 alleles. It has been predicted as benign with 
Polyphen2, and alternatively, damaging with the SIFT algorithm. LTBP2 is located at 
position 14q24.3, which is close to our linked region of interest. This gene encodes the 
latent transforming growth factor beta binding protein 2, which is an extracellular matrix 
protein that plays a role in cell structure and adhesion. Based on the Online Mendelian 
Inheritance in Man (OMIM) database, LTBP2 has been connected to various eye 
disorders including congenital forms of glaucoma, but has not been associated with 
aneurysm formation or other vascular anomalies. Though this variant did not pass our 
established filtering criteria for family R1256, its potential involvement in IA will be 
explored in detail in subsequent analyses.  
 
3.7 Digenic Inheritance in Family R1352 
 
 The validation of 4 filtered variants in R1352, that were each found in 6/7 
exomes, led to the consideration of alternate modes of inheritance. The possibility of 
digenic inheritance was explored in the context of these 4 candidate variants (C4orf6 
c.1A>G, GIGYF2 c.3494A>G, ATP1A4 c.1798C>T, and RP1L1 c.202C>T). Digenic 
inheritance is defined as a case where “variant genotypes at two loci explain the 
phenotypes of some patients and their unaffected (or mildly affected) relatives more 
clearly than the genotypes at one locus alone” (Schaffer, 2013). To better depict the co-
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existence of these genetic variations in family R1352, their dual segregation was shown 
on the condensed pedigree (Figures 21-26). Six different combinations of these 4 variants 
were depicted on the pedigree, to show the various possibilities of digenic inheritance. 
The co-segregation of C4orf6 c.1A>G and GIGYF2 c.3494A>G is shown in Figure 21, 
which demonstrates an interesting pattern. It appears that each variant is being 
transmitted from a different side of the pedigree, culminating in the presence of both 
variants in the 4 affected siblings: Z1039, Z1040, Z1497 and Z1508, and the half-sibling 
Z1507. Individual Z1651 has the C4orf6 variant, while Z1533 has the GIGYF2 variant. 
Tested unaffected relatives have 1 of these variants, or neither of them.  
 A similar pattern was seen for GIGYF2 c.3494A>G and RP1L1 c.202C>T, though 
unaffected member Z1504 had both variants (Figure 22). In the combinations of C4orf6 
c.1A>G and ATP1A4 c.1798C>T (Figure 23), and ATP1A4 c.1798C>T and RP1L1 
c.202C>T (Figure 24), the 5 siblings also share both variants. The main difference is that 
Z1507 is homozygous for ATP1A4 c.1798C>T. In each case, none of the unaffected 
relatives have both variants.  
 Finally, the pair of ATP1A4 c.1798C>T and GIGYF2 c.3494A>G does not appear 
to be indicative of digenic inheritance (Figure 25). In this scenario, individual Z1651 has 
neither of the 2 variants, though the remaining 6 affected individuals have both. Three of 
the unaffected relatives (Z1506, Z1535 and Z1538) have both variants as well. Similarly, 
the C4orf6 c.1A>G and RP1L1 c.202C>T pair does not clearly fit the digenic inheritance 
model (Figure 26). Individual Z1533 does not have either of these variants, and 1 
unaffected relative, Z1660 has both. The consideration of digenic inheritance in the 
context of familial IA will be explored in the Discussion.  
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4. Discussion 
4.1 IA Mode of Inheritance     
 It is widely acknowledged that there is a genetic component to the aggregation of 
IA cases in families. Presently, several statistical associations have been identified, 
though no causal variants for IA predisposition have been confirmed. Through the study 
of two multiplex families from Newfoundland and Labrador, it has become evident that 
inheritance of IA is a complex genetic phenomenon. At the onset of this study, it was 
hypothesized that there were one or more strongly penetrant variants in our cohort that 
were contributing to IA predisposition, and that these variants would be rare or novel. It 
was predicted that these families were exhibiting either autosomal dominant or recessive 
inheritance of an IA causative variant, based on strong family history and pedigree 
characteristics, in concert with environmental risk factors. A distinct lack of homozygous 
variants may indicate that IA is not an autosomal recessive disorder in these 
Newfoundland families, and that this interpretation of the pedigrees should no longer be 
considered. If these families exhibited autosomal recessive inheritance, then all affected 
individuals (with the exception of phenocopies) would have a homozygous variant in a 
single gene or compound heterozygous variants. However, there is also the possibility 
that somehow homozygous variants were not called with accuracy through the MUGQIC 
bioinformatics pipeline. Further inquiry into the absence of shared, rare homozygous 
variants is necessary. 
 Our results revealed incomplete segregation of several variants of unknown 
functional consequence, and an overall lack of shared filtered variants between the two 
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families. As well, none of the filtered variants overlapped with significant candidate 
genes or GWAS loci from previous IA association studies. As most large-scale 
association studies have focused on sporadic IA, it can be hypothesized that different 
genetic factors may be associated with familial IA development.  
 Based on our knowledge of modifiable risk factors such a smoking, hypertension 
and alcohol use in these families, it is quite possible that one or more affected individuals 
may be phenocopies in our study. IA can occur sporadically as a consequence of lifestyle 
and environment, and manifest with the same level of severity as familial IA. The 
presence of phenocopies would explain the absence of a shared candidate variant among 
all affected individuals within a single family. In this study, I chose to examine variants 
found in at least 4/5 exomes from R1256, and 6/7 from R1352. This low phenocopy 
estimation was selected based on the prediction that most members of the family would 
in fact share a genetic risk factor. In previous family-based WES studies of IA, Farlow et 
al. (2015) and Yan et al. (2015) did not account for phenocopies, and only kept variants 
that were shared by all affected relatives with the phenotype. Feng et al. (2011) discussed 
the importance of accounting for phenocopies when studying complex disease in 
families, given that sporadic cases occur frequently in the general population. Further 
examination of the clinical data, and a less strict estimation of phenocopy percentage 
could be used in future studies of the NL cohort.  
 Incomplete penetrance may also be an issue to consider as we move forward with 
this study. We chose to not include an unaffected individual in our exome cohort in 
response to this possibility. Therefore, our segregation analysis in unaffected family 
members should be treated with caution, as variant carriers may not develop IA. To cover 
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all possibilities of disease pathogenesis, alternate modes of inheritance could also be 
explored. It is possible that IA exhibits oligogenic or polygenic inheritance, and that our 
focus on monogenic risk factors is not fitting for this disease model. As our knowledge of 
the genetic etiology of IA grows, more questions continue to arise. The in-depth 
exploration of top candidate variants in our cohort, ideally through functional studies, is 
necessary to determine their relevance as we move forward with alternate study designs 
and new hypotheses.  
 
4.2 Predicted Pathogenicity of Top Candidate Variants  
 
 Functionally, the top candidate genes in this study, C4orf6, GIGYF2 and 
SPDYE4, do not have an obvious role to play in the pathophysiology of IA. As a result of 
our continually growing knowledge of the intricate human genome, these genes may have 
functions in vascular biology that are not yet known. To further assess the predicted 
pathogenicity of these variants, statistical methods can be used to determine the 
likelihood that these variants are involved in IA predisposition.  
  Moller, Clarke and Maehle (2011) developed a set of equations called the 
simplified method for segregation analysis (SISA), which can be used to statistically 
interpret variant segregation and penetrance in a family. This method is based on the 
value “n” that equals the number of informative meioses in a family. The value “n” is 
denoted as the number of affected variant carriers minus one. This value can be used to 
calculate the probability of co-segregation of the phenotype and a genetic variant by 
chance, (1/2)
n
. For SPDYE4 c.103C>T, “n” equals 9, and the probability of co-
segregation by chance is 0.001953125, or 0.195%. This means that there is a high 
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probability that the segregation of this variant with the disease is unlikely to be due to 
chance. However, this calculation does not include obligate carriers, and should just be 
used as a supportive piece of evidence, rather than a definitive clue toward pathogenicity. 
This calculation was also performed for C4orf6 c.1A>G, where “n” equals 5 (number of 
known affected carriers minus one).  In this case, the probability of co-segregation by 
chance is equal to 0.03125, or 3.125%. This is the same probability for GIGYF2, 
c.3494A>G, as well as the ATP1A4 and RP1L1 variants.   
 
4.3 Digenic Inheritance in Family R1352  
 
 The presence of 4 variants of interest in R1352, each with an equal probability of 
cosegregation by chance, led to the consideration of digenic inheritance in this family.  
Schaffer (2013) stated that digenic inheritance encompasses cases where both loci are 
responsible for determining affected status, or where the combination of both loci leads to 
a “substantial change in severity, or a substantial change in age of onset”.  Within this 
definition, one locus may be the primary variant, or both variants may be equally 
responsible for the phenotype (Schaffer, 2013). The limited scope of studying monogenic 
inheritance alone may not be sufficient to explain the features of genetically 
heterogeneous diseases. The introduction of WES and other high throughput methods has 
allowed researchers to uncover more than one candidate variant that segregates in a 
single family.  
 The first case of digenic inheritance was described by Kajiwara et al. (1994), in 
their report on retinitis pigmentosa. In three unrelated families, only individuals with both 
a missense mutation in PRPH2 and a null mutation in ROM1 exhibited retinitis 
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pigmentosa. The two genes, PRPH2 and ROM1, are located on different chromosomes, 
and encode proteins that are known to interact. Since this time, digenic inheritance has 
been observed in a multitude of heritable diseases, including several adult-onset disorders 
with varied modes of inheritance. Tang et al. (2006) reported on a family with early-onset 
Parkinson’s disease, exhibiting digenic inheritance. Previously, autosomal recessive 
inheritance of this disease, via homozygous mutations in the PINK1 and DJ-1 genes had 
been described. However, the mechanism by which heterozygous variants in these genes 
led to the phenotype was unclear. The study by Tang et al. (2006) focused on a Chinese 
family, with two sisters that developed Parkinson’s disease in their late 20s. Both siblings 
shared heterozygous variants in PINK1 and DJ-1, and two unaffected relatives had either 
the PINK1 or DJ-1 variant alone. Another one of their unaffected siblings had both 
variants, which the authors attributed to decreased penetrance in this early onset form of 
the disease.  
 In the R1352 Results, it was determined that the segregation of C4orf6 c.1A>G 
and GIGYF2 c.3494A>G was of particular interest. In this scenario, the 4 siblings 
(Z1039, Z1040, Z1497, Z1508) and 1 half-sibling (Z1507) share both variants. Individual 
Z1533 has the GIGYF2 variant alone, while Z1651 has the C4orf6 start-lost variant. 
Schaffer (2013) emphasized that strong supportive evidence for digenic inheritance 
includes the comparison of phenotypic data between affected family members. In our 
study, we were fortunate to have access to a wealth of clinical information from each 
family.  The age range of diagnosis for the 5 affected relatives that share both variants 
was 40-50 years. The 2 individuals that have only 1 of the variants, Z1651 and Z1533, 
were diagnosed at age 56 and 65, respectively. It is possible that the combination of both 
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loci could cause a slightly earlier age of onset, though the age of diagnosis might have 
also been influenced by the year that they were recruited to the IA study. For example, 
the proband, Z1039, was diagnosed at age 43, in 2005, whereas individual Z1533 was 
diagnosed by CT scan in 2010. As well, patient diagnosis either occurred following 
clinical presentation (i.e. complications or rupture) or after clinical screening, which must 
be taken into account when assessing age of diagnosis.  
 IA location or size does not appear to be correlated with the presence of both 
variants versus one. Z1651 had an aneurysm measuring 1.5-2 mm, and Z1533 had a 
much larger 9.4x5.6 mm aneurysm. Across the entire family, there was variance in IA 
location (Table 6), and all individuals with both variants do not share a common site or 
size in the Circle of Willis.  
 In order to explore protein-protein interactions between C4orf6, GIGYF2, RP1L1, 
and ATP1A4, the STRING v.10 database was queried. The “Search Tool for the Retrieval 
of Interacting Genes/Proteins” or STRING, is an online database of known and predicted 
interactions between genes and proteins, that have been integrated from multiple sources 
for ease of use (Szklarczyk et al., 2015). Upon entering the names of specific proteins, 
STRING generates a map, with coloured lines connecting interacting proteins. For the 4 
genes of interest in R1352 there were no known interactions detected. Therefore, this 
database does not provide any supporting evidence for the digenic inheritance hypothesis. 
However, digenic inheritance is not solely dependent on protein-protein interaction, and 
there are a myriad of analyses that could be performed. Replication of these variants in 
additional IA families from NL would contribute to the plausibility of this mode of 
inheritance.  
 135 
4.4 Implications of Low Impact Variants  
 
 To assess the potential role of synonymous variation in IA, I decided to apply the 
same filtering stategy, as outlined in Figure 11, to the low impact variant lists from 
families R1352 and R1256. My study design allowed an in-depth analysis of the 
moderate and high impact SNVs and small INDELs present in the exome and narrow 
exon/intron boundaries. Low impact variants are less commonly implicated in heritable 
disease, though several cases exist. For example, a synonymous variant, c.313C>T, in the 
IRGM gene has been associated with Crohn’s disease susceptibility, and is a predicted 
causal variant for this complex immune disease (Brest et al., 2011). In addition to 
statistical association, synonymous mutations have also been classified as the direct cause 
of heritable disease. A synonymous mutation in exon 3 of the FGFR2 gene has been 
reported as the cause of an autosomal dominant bone disease, Crouzon syndrome, in 
multiple families (Del Gatto & Breathnach, 1995).  
 There is a growing body of evidence that supports the potential effect of 
synonymous variation on the human genome. Sauna & Kimchi-Sarfaty (2011) have 
emphasized that these variants can cause aberrant mRNA splicing, and also impact the 
stability of mRNA molecules. Our inability to demonstrate the mechanisms by which 
synonymous variants can cause different diseases is currently one of the roadblocks that 
prevents many research groups from including low impact variants in their analyses. As 
our knowledge of the human genome and its complexities increases, more synonymous 
changes may be implicated in heritable disease.  
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 In family R1352, 2 of the filtered synonymous variants, APBB2 c.231G>A and 
COL6A3 c.702C>T were of interest functionally.  The APBB2 gene encodes amyloid beta 
A4 precursor protein-binding family B member 2 protein. This gene has been associated 
with late-onset Alzheimer disease (Y. Li et al., 2005). Besides beta-amyloid binding, 
other known protein functions include extracellular matrix organization and regulation of 
apoptosis, which may be of interest in IA pathophysiology. The COL6A3 gene is 
responsible for encoding the alpha 3 chain of type 6 collagen. Variants in this gene have 
been connected to Mendelian inheritance of Bethlem myopathy 1 (Baker et al., 2007), 
Dystonia 27 (Zech et al., 2015), and Ullrich congenital muscular dystrophy 1 (Baker et 
al., 2005). Collagen is an essential structural component of the vascular wall, though this 
gene has not been connected to any aneurysm phenotypes. In our NextGene
® 
results, 
there was a rare heterozygous missense variant in the same gene, that was found in 6/7 
exomes from this same family. The COL6A3 c.5610C>T variant was not called by the 
MUGQIC bioinformatics pipeline, and thus was not validated by Sanger sequencing.  
Interestingly, this variant was only absent from individual Z1651. This same family 
member was also the only 1 of 7 that did not have the COL6A3 c.702C>T synonymous 
variant. Individual Z1651 could possibly be a phenocopy, and this gene could be 
explored further in upcoming research plans.  
 In family R1256, 2 novel synonymous changes were detected in the TNRC18 and 
FAM83G genes, and were called in all 5 exomes. TNRC18 encodes the trinucleotide 
containing 18 protein, which may be involved in chromatin binding and silencing. 
FAM83G is also known as family with sequence similarity 83, member G. This gene is 
found in a complex with the SMAD1 gene. SMAD1 is a transforming growth factor beta 
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signaling protein, and has been linked to various diseases, including pulmonary arterial 
hypertension (Nasim et al., 2011). However, this disease-gene connection has not been 
confirmed. Previously reported variants in OTOGL, PCDH9 and GPR179 also passed the 
filtering strategy, and were detected in all five exomes. OTOGL has specific expression 
in the inner ear, while PCDH9 is involved in the mediation of cell adhesion in the 
nervous system. GPR179 is involved in the vision pathway, and has been associated with 
a congential form of night blindness (Audo et al., 2012). Sanger sequencing was not used 
to validate any of these rare, synonymous variants that passed our filtering methodology. 
At this time, there are insufficient bioinformatics tools and functional assays available to 
assess the predicted pathogenicity of synonymous variation in the genome. Therefore, it 
would be difficult to establish a link between any of these variants and IA predisposition, 
based primarily on segregation. As well, none of these synonymous changes are found in 
previously reported IA-associated genes, or genes with a clear functional relevance to this 
disease. However, these additional analyses could be helpful when studying additional IA 
families from the Newfoundland and Labrador population. It is possible that one or more 
of these rare, synonymous variants segregates with IA in another family as well.  
 
4.5 Strengths and Limitations of Study   
 
 This study design had several strengths, including the selection of WES 
technology for disease gene discovery. The emergence of WES has expanded our ability 
to visualize the unique variation present in the coding portion of the human genome. As 
the cost and time associated with WES has declined, its accessibility and use in disease-
gene discovery has rapidly increased. The use of a WES-based study design allowed me 
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to visualize all of the coding variants in our 12-patient cohort in a high-throughput 
manner, which is a definite strength in comparison to traditional sequencing methods. 
Additionally, access to a wealth of clinical information and the recruitment of multiplex 
families was a major strength of our research. Established diagnoses and strong family 
histories allowed us to build a filtering strategy around the exploration of shared variants 
in multiple family members.   
 Consequently, many of the limitations of this study also stemmed from the 
particular nature of WES technology, and the uncertainty surrounding the mode of 
inheritance of IA. The major challenge presented by WES is the shear abundance of data 
generated from a single exome. Accurately calling and annotating the thousands of 
variants from a single individual is a task that requires immense bioinformatics support. 
Deciding the best way to prioritize the thousands of variants in an exome, and 
determining which ones are likely instrumental in human disease is an ongoing challenge.  
 Each step of my filtering strategy was carefully planned, based on consultation of 
other family-based research studies that have utilized WES. As none of the top candidate 
variants in my study segregated completely with IA, it is possible that the filtering steps 
were too stringent for the characteristics of this disease. Adjustment of the MAF cut-off 
to 5%, for example, would allow us to consider more common variants, which may be 
involved in IA predisposition in conjunction with other risk factors. However, this dataset 
would have been much larger, and issues with variant prioritization would still be 
present. Gaps in the available data such as gene function and expression in bodily tissues 
is a definite limitation to our ability to interpret variants with accuracy (Figure 27).  
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Figure 27. The increasing gap between the accessibility of genomic data and our 
ability to interpret variants and their clinical implications. Reprinted from Cutting 
(2014) with copyright permission. 
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 Technical limitations must also be considered in WES studies. Failed exome 
capture and low coverage in certain regions of the genome are both possible 
complications. For example, areas of the genome with a high GC content may be more 
difficult to capture with accuracy (Schwartzentruber, 2012). DNA sample quality can 
also impact overall coverage.  As well, due to quality control methods, such as filtering 
out areas of low read depth, certain regions of the exome may be unrepresented. As 
methods of WES and complimentary data analysis become more powerful, the 
identification of candidate variants for IA within these regions may be possible. Variant 
calling errors and software glitches can also occur, which are an unavoidable 
consequence of computational analysis. We outsourced our WES and bioinformatics 
support, as we did not have the technology and infrastructure to perform these 
experiments at the time. Therefore, it was not possible for us to oversee each step of the 
analyses.  
 Another limitation of a WES-based study is that this technology only captures 1% 
of the entire human genome. Though 85% of the mutations identified in Mendelian 
diseases are located in the exome, this study design ignores the non-coding portion of the 
genome, which may have an unknown role to play in IA inheritance (Ng et al., 2009). 
Ultimately, the unknown mode of inheritance of IA is a major limitation to our ability to 
identify causal variants in our cohort. As well, WES only allows the detection of SNPs 
and small INDELs. In the context of complex disease, Wang et al. (2013) discusses the 
need to also evaluate low frequency variants, copy number variants, and also other 
structural changes.  
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Finally, there were several faults within the MUGQIC pipeline and NextGene
®
, 
which limited our ability to accurately annotate all variants. The major fault lies within 
the dbNSFP database, which was used in both the MUGQIC and NextGene
®
 analyses. 
This database has an abundance of missing scores that may need to be imputed manually 
for certain SNPs, and this database must be re-downloaded and installed within 
NextGene
® 
periodically to maintain updates. The incorporation of ExAC Browser and 
NHLBI Exome Variant Server allele frequencies would be a welcome addition to the 
NextGene
®
 track manager as well.  The utility of NextGene
®
 for our laboratory’s 
purposes is still undetermined. This software is still a relatively new development, and 
has not been referenced in many published works. As newer versions of NextGene
®
 are 
released, and we gather larger amounts of exome data, its desktop convenience may be of 
interest for our data analysis needs.  
 
4.6 Future Directions  
 
 In the immediate future, there are plans to complete a copy number variant (CNV) 
analysis for the 12 individuals that were selected for WES in this study. As WES only 
covers SNVs and small INDELs, it is possible that a larger chromosomal abnormality 
may be present in these families. To identify CNVs in these samples, a genome-wide 
SNP chip assay will be used, in conjunction with analytical software. The unknown 
genetic etiology of IA opens up a wide variety of possible study designs for our research 
team. As suggested earlier, the low, moderate and high impact lists for these families can 
be re-filtered in a variety of ways. It is possible that a more common genetic factor is 
responsible for IA development, in conjunction with environmental agents. Therefore, the 
 142 
MAF cut-off could be extended to the 2-5% range. To compensate for the additional 
variants, a different filter could be included such as Polyphen2 scores, or the presence of 
a functional keyword such as “vascular” in gene descriptions. There are endless 
opportunities for re-design of the filtering strategy, which may be adjusted in the coming 
years as research concerning best practices for exome data analysis and disease gene 
discovery undergoes advancement.  
 It would also be beneficial to connect with potential collaborators from other 
institutions that have conducted WES of familial IA cases. It is possible that there are 
shared variants between our project and another independent study. The comparison of 
filtered high, moderate, and low impact lists, and discussion about IA mode of 
inheritance in general, with other IA researchers could be a future direction. 
 Though my research has focused specifically on families R1256 and R1352, 
future work will involve the other families in the NL cohort that have a high incidence of 
IA. Six additional families have 4 or more affected members, which can be analyzed 
through WES. Comparisons could then be drawn between multiple families, to look for 
shared genetic risk factors for IA in this population. Ultimately, our future pursuits will 
lead to the functional analysis of any variants that have strong evidence for causation. A 
zebrafish model is proposed to demonstrate the effects of these genetic variations in the 
cerebral vasculature and overall body. Zebrafish are a highly useful model organism for 
this project, as they have rapid development and their embryos are optically clear, in 
comparison to a mouse model (Walcott & Peterson, 2014) Thus, the vascular system of 
the zebrafish can be viewed in real-time through a microscope, to investigate the 
formation of arterial lesions, and view alterations in hemodynamics and overall vessel 
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structure (Walcott and Peterson, 2014). Gene knock-down through the use of morpholino 
oligonucleotides in zebrafish would allow us to model the effects of deleterious variants, 
in a cost-effective and high throughput manner (Phillips & Westerfield, 2014). This is a 
practical model for the investigation of a disease of unknown genetic etiology. 
 
4.7 Conclusion  
 This study marks the first investigation into genetic risk factors for familial IA in 
the Newfoundland and Labrador population, which is known to have an increased 
prevalence of several heritable diseases. Through the use of WES technology, the exomes 
of 12 affected individuals from two families – R1352 and R1256, were analyzed. 
Filtering of this data resulted in the identification of several candidate variants, though 
none of the variants segregated completely with IA incidence. In R1352, the high impact 
variant C4orf6 c.1A>G was identified as a top candidate, and the moderate impact variant 
GIGYF2 c.3494A>G was also highlighted as a variant of interest. In R1256, SPDYE4 
c.103C>T was the only variant to segregate in the majority of affected family members. 
Each of these three variants was absent from 100 population controls from Newfoundland 
and Labrador. Functional annotation and replication of these variants in other affected 
individuals would be necessary to generate more evidence for pathogenicity. Further 
genetic research in this province may culminate in better outcomes for familial IA 
patients, and result in the ability to diagnose IA through genetic testing methods, leading 
to more effective treatment and preventative measures. The results generated from this 
study have stimulated multiple new research questions and hypotheses, which will be 
exciting to pursue in the years to come. 
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Appendices 
Appendix A: Promega Wizard® Genomic DNA Extraction 
 
Materials:  
1) Blood collected in EDTA tubes  
2) Laminar flow biosafety containment cabinet  
3) Centrifuge 
4) Vortex 
5) 50 ml sterile centrifuge tubes 
6) 1.5 ml sterile microcentrifuge tubes 
7) Promega Wizard® Genomic Purification Kit Cat #PRA-1620 
8) Isopropanol  
9) 70% Ethanol 
10)  Disposable 15 ml pipettes 
11)  Motorized pipette 
 
Protocol for 12-16 ml of whole blood: 
1) Add 30 ml of Cell Lysis Solution to a 50 ml sterile centrifuge tube. 
2) Gently rock the tubes of blood until mixed thoroughly. Add 12-16 ml of whole blood 
to the centrifuge tube containing the Cell Lysis Solution. Invert the tube 5-6 times. 
3) Incubate the mixture at room temperature for 10 minutes (invert 5-6 times halfway 
through incubation). 
4) Centrifuge the mixture at 2000 g for 10 minutes. 
5) Remove and discard as much supernatant as possible without disturbing the pellet at 
the bottom of the tube. 
6) Vortex the tube, add 10 ml of Nuclei Lysis Solution, and vortex again for 20 seconds. 
7) Add 3.3 ml of Protein Precipitation Solution. Using a motorized pipette, mix the 
solution 5-6 times. 
8) Centrifuge at 2000 g for 10 minutes.  
9) Add 10 ml of Isopropanol to a new sterile 50 ml centrifuge tube. 
10) Gently pour the supernatant into the centrifuge tube containing the Isopropanol. 
11) Centrifuge at 2000 g for 2 minutes. 
12) Wash with 70% ethanol and repeat step 11. 
13) Let air dry. 
14) Add 400 µl of Rehydration Buffer, let sit overnight. 
15) Mix sample briefly and quantify concentration. 
16) DNA sample can be stored at 4ºC or frozen for an extended period. 
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Appendix B: Primer Sequences and PCR Protocols 
 
Primer Name Primer Sequence (5’- 3’) Product 
Size  
PCR Protocol 
Used 
ATP1A4_P600S_F CTGGGGTGAGAAATCAAGGA 382 bp Standard 
(62°/30 cycles) ATP1A4_P600S_R AGGAAACAGAAATCCGCTCA 
C4ORF6_start_F GCCAGCCTCCTACCTCAAAT 364 bp Standard 
(62°/30 cycles) C4ORF6_start_R GAGCACCTTCCGACTCACTC 
CCDC3_L73V_F GGCCGAGACCATCGTGTA 216 bp Standard 
(62°/30 cycles) CCDC3_L73V_R GAGTGGCACGAGAAGTAGCC 
CCDC3_FS_F GGAGCGAGTGAAGAAGGTCA 236 bp Standard 
(60°/30 cycles) CCDC3_FS_R GCTGCATGTACGAAACCTCA 
DOPEY1_A2301V_F CAAACATTCCACCCGCCTTG 590 bp Standard 
(68°/30 cycles) DOPEY1_A2301V_R CCGATAACTCTGCTGTGCCA 
GIGYF2_H1165R_F TCCCCAAATTACTTCAGCCTT 529 bp Standard 
(62°/30 cycles) GIGYF2_H1165R_R GGTACCGCATACACCACACT 
HSPBP1_G26GAAD_F GACTTTGGGGAAGGGTCCTG 511 bp Touchdown-A 
(T1: 64.5°, 10 cycles, 
T2: 60°, 25 cycles) 
HSPBP1_G26GAAD_R CTCCCCAAGTCACACTTCCC 
KNDC1_A896S_F GGGGAACGTGATGACCAGAG 520 bp Standard 
(67.9°/35 cycles) KNDC1_A896S_R TGCCCGTTGACCACCTTAAA 
MAML3_F CAGTCCCCTCAAACTCCAAA 394 bp Standard 
(62°/30 cycles) MAML3_R AGGCTTGGGGGTACATCATT 
MTG1_P204L_F TGGGAGCAGAAGACAAGCTG 570 bp Standard 
(66°/30 cycles) MTG1_P204L_R CTGGTCCGTCAAATGGGGAA 
MUC4_D997N_F TGTCACCTTCAGGGTCTGGT 850 bp N/A 
MUC4_D997N_R GCGGAAGGGATGGTTACA 
MUC16_G13530S_F GAGCAGTGGGGTTTCTCTCC 525 bp Standard 
(66°/30 cycles) MUC16_G13530S_R GAGGTGGTGGGAACAGGAAG 
MYO18A_F GGCCATTCGCTGTGTACAGA 395 bp  Standard  
(62°/30 cycles) MYO18A_R GGCATGTCCCCAATAGCAGA 
OCIAD1_F TCAGTCTGTAACGGCAGGTG 186 bp Standard 
(60°/30 cycles) OCIAD1_R CCATAACGGCATCCTTCCTA 
POU3F1_A28-_F ACCACCGCGCAGTACCTG 585 bp N/A 
POU3F1_A28-_R CTCGTGGCCATCCTCGTG 
RP1L1_L68F_F TGGAGTGGAGCACATTTGGG 512 bp Standard 
(68°/30 cycles)  RP1L1_L68F_R GAGCAGTGGGGTTTCTCTCC 
SPDYE4_P35S_F ATTATGGCCAGTGGTCAAGC 311 bp Standard  
(62°/30 cycles) SPDYE4_P35S_R TCATTGCTCCCCAGACTTTC 
TRPA1_F AATGGATGAAGACAACGATGG 242 bp Standard 
(62°/30 cycles)  TRPA1_R ACGCCCATAACTTGGAAAAA 
ZFPM1_F CCGTTTCAGCCTTCGCTCTA 523 bp N/A 
ZFPM1_R ACGTACTGCGGAAGGAACAG 
ZPBP2_T208S_F TGCACATGGAATTCAGCACT 297 bp Touchdown-A 
(T1: 67°, 15 cycles, 
T2: 60°, 19 cycles) 
ZPBP2_T208S_R CTTGAGCCCAGGAGTTTGAG 
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Appendix C: Thermocycler Protocols 
 
1. ExoSap  
 
Step Temperature Duration 
1 37 °C 30 minutes 
2 80 °C 15 minutes 
3 4 °C Hold 
 
2. ABISeq 
 
Step Temperature Duration 
1 96 °C 1 minutes 
2 96 °C 10 seconds 
3 50 °C 5 seconds 
4 60 °C 4 minutes 
5 Return to Step 2 (34 cycles) 
6 4 °C Hold 
 
3. Denature 
 
Step Temperature Duration 
1 95 °C 2 minutes 
2 4 °C Hold 
 
4. Standard (PCR) 
 
Step Temperature Duration 
1 95 °C 2 minutes 
2 95 °C 30 seconds 
3 Annealing Temp. (varies) 30 seconds 
4 72 °C 1 minute 
5 Return to Step 2 (# cycles varies)  
6 72 °C 10 minutes 
7 4 °C Hold 
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5. Touchdown-A (PCR) 
 
Step Temperature Duration 
1 95 °C 2 minutes 
2 95 °C 20 seconds 
3 Annealing Temp. 1 (varies) 45 seconds 
4 72 °C 45 seconds 
5 Return to Step 2 (10-15 cycles, decreasing at 0.5 °C increments) 
6 95 °C 20 seconds 
7 Annealing Temp. 2 (varies) 45 seconds 
8 72 °C 45 seconds 
9 Return to Step 5 (15-20 cycles) 
10 72 °C 5 minutes 
11 4 °C Hold 
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Appendix D: Additional Moderate Impact Variants in Family R1256 
 
1. Variants that passed filtering criteria, were detected in 5/5 exomes, and were 
previously reported in dbSNP:  
 
Gene Chr. 
Position 
Status in 
dbSNP (rs#) 
Variant 
Details  
 
 
# 
Het / # Hom for 
Minor Allele / # 
Hom for 
Reference Allele  
MAF in 
MUGQIC 
Controls 
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
KIAA0040 1q25.1 rs150137790 c.217_225delAAGAA
GAAG 
p.K73_K75del 
Inframe Del 
3 / 2 / 0 0.12% 
(1/848) 
0.4964% 
(83/16720) 
LSG1 3q29  rs114485048 c.1039C>T 
p.R347W 
Missense 
5 / 0 / 0 0.94% 
(8/848) 
0.1805% 
(222/122962) 
SIM1 6q16.3 rs145479047 c.1082C>T 
p.T361I 
Missense 
5 / 0 / 0 0%  
(0/848) 
0.2145% 
(263/122600) 
ZMIZ2 7p13 rs189007540 c.1640G>A 
p.S547N 
Missense 
5 / 0 / 0 0%  
(0/848) 
0.09167% 
(112/122174) 
PSPH 7p11.2 rs75395437 c.268G>A 
p.G90S 
Missense 
5 / 0 / 0 0%  
(0/848) 
0.514% 
(608/118296) 
PSPH 7p11.2 rs73343757 c.249A>C 
p.Q83H 
Missense 
5 / 0 / 0 0%  
(0/848) 
0.8515% 
(997/117092) 
ANKRD30A 10p11.21 rs202149101 c.1232G>T 
p.R411M 
Missense 
5 / 0 / 0 0%  
(0/848) 
0.06915% 
(83/120022) 
GPR123 10q26.3 rs144212964 c.1283G>A 
p.R428Q 
Missense 
5 / 0 / 0 0.24% 
(2/848) 
0.2666% 
(45/16882) 
ZFPM1 16q24.2 rs149145771 c.1334_1339delCTC
TGG 
p.L446_A447del 
Inframe Del 
0 / 5 / 0 0.35% 
(3/848) 
0% 
(0/118) 
PHF12 17q11.2 rs200985028 c.1473C>G 
p.H491Q 
Missense 
4 / 1 / 0 0%  
(0/848) 
0.1009% 
(124/122950) 
MYO18A 17q11.2 rs777985641 c.3704C>T 
p.P1235L 
Missense 
2 / 3 / 0 0.12% 
(1/848) 
 
0.000828% 
(1/120720) 
KANSL1 17q21.31 rs74867664 c.2698G>A 
p.G900R 
Missense 
5 / 0 / 0 0.24% 
(2/848) 
0.1078% 
(132/122452) 
DGCR6 22q11.21 rs146390355 c.392G>A 
p.R131H 
Missense 
5 / 0 / 0 0.71% 
(6/848) 
0.3033% 
(355/117050) 
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2. Variants that passed filtering criteria, were detected in 4/5 exomes, and were 
previously reported in dbSNP: 
 
Gene Chr. 
Position 
Status in 
dbSNP (rs#) 
Variant 
Details  
 
# Het / # Hom for 
Minor Allele / # 
Hom for 
Reference Allele 
MAF in 
MUGQIC 
Controls 
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
KIAA0319L 1p34.3 rs144951042 c.700A>G  
p.T234A 
Missense 
4 / 0 / 1 0%  
(0/848) 
0.0838% 
(103/122912) 
DYSF 2p13.2 rs771062534 c.1609G>A 
p.V537M 
Missense 
4 / 0 / 1 0% 
(0/848) 
0.006109% 
(5/81840) 
FAHD2A 2q11.1 rs200437887 c.281C>T 
p.S94L  
Missense 
4 / 0 / 1 0%  
(0/848) 
0.06028% 
(71/117782) 
RNF149 2q11.2 rs143827530 c.416A>G 
p.N139S 
Missense 
4 / 0 / 1 0%  
(0/848) 
0.1776% 
(199/112024) 
FANCD2 3p25.3 rs35625434 c.983G>A 
p.R328Q 
Missense 
4 / 0 / 1 0.35% 
(3/848) 
0.3032% 
(480/122080) 
SLC15A2 3q13.33 rs748018463 c.1301A>G 
p.H434R 
Missense 
4 / 0 / 1 0.12% 
(1/848) 
0.005767% 
(7/121370) 
MUC4 3q29 rs779985296 c.7189G>C 
p.D2397H  
Missense 
4 / 0 / 1 0%  
(0/848) 
0.04447% 
(11/24736) 
ABLIM2 4p16.1 rs370025292 c.481G>A 
p.V161I 
Missense 
4 / 0 / 1 0%  
(0/848) 
0.004107% 
(5/121740) 
FOXP4 6p21.1 rs41273784 c.97G>A 
p.G33R  
Missense 
4 / 0 / 1 0.59% 
(5/848) 
0.3616% 
(437/120854) 
GTF2E2 8p12 rs2978277 c.548A>G 
p.K183R  
Missense 
4 / 0 / 1 0.71% 
(6/848) 
0.3661% 
(449/122660) 
WRN 8p12 rs78488552 c.3785C>G 
p.T1262R  
Missense 
4 / 0 / 1 0.59% 
(5/848) 
0.2753% 
(338/122784)  
BRINP1 9q33.1 rs142894245 c.1046C>T 
p.T349M  
Missense 
4 / 0 / 1 0.24% 
(2/848) 
0.2099% 
(258/122902) 
ANTXRL 10q11.22 rs148029033 c.509A>G 
p.N170S 
Missense 
4 / 0 / 1 0.47% 
(4/848) 
0.07254% 
(12/16542)  
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AGAP7 10q11.22 rs201609209 
 
c.362T>C 
p.L121S  
Missense 
3 / 1 / 1 0.59% 
(5/848) 
0.3333% 
(219/65700) 
MYOF 10q23.33 rs201634420 
 
c.4534C>T 
p.R1512W  
Missense 
4 / 0 / 1 0.83%  
(7/848) 
0.2305% 
(262/113648) 
LRRC56 11p15.5 rs138291757 
 
c.655G>A 
p.V219M  
Missense 
4 / 0 / 1 0.59% 
(5/848) 
0.6479% 
(105/16206) 
LDHA 11p15.1 rs34305721 
 
c.434G>C 
p.G145A  
Missense 
4 / 0 / 1 0.59% 
(5/848) 
0.2521% 
(310/122960) 
IFITM5 11p15.5 rs747064580 c.268G>A 
p.A90T 
Missense 
4 / 0 / 1 0%  
(0/848) 
0.004152% 
(5/120416) 
CPT1A 11q13.3 rs80356779 
 
c.1436C>T 
p.P479L  
Missense 
4 / 0 / 1 0.47% 
(4/848) 
0.001627% 
(2/122898) 
C11orf30 11q13.5 rs184345272 
 
c.2861T>G 
p.L954R  
Missense 
3 / 1 / 1 0.12% 
(1/848) 
0.1952% 
(237/121386) 
MOGAT2 11q13.5 rs373540522 c.299C>A 
p.S100Y 
Missense 
3 / 1 / 1 0%  
(0/848) 
0.01155% 
(14/121212) 
GSG1 12p13.1 rs148537880 
 
c.391G>A 
p.E131K  
Missense 
4 / 0 / 1 0%  
(0/848) 
0.01546% 
(19/122894) 
OR11H4 14q11.2 rs142720326 
 
c.55G>A 
p.V19M  
Missense 
4 / 0 / 1 0.24% 
(2/848) 
0.1199% 
(147/122594) 
LTBP2 14q24.3 rs201591982 
 
c.2657C>A 
p.T886K  
Missense 
4 / 0 / 1 0.24% 
(2/848) 
0.07206% 
(70/97140) 
NIPA1 15q11.2 rs549007670 c.40_48delGCGGC
GGCC 
p.A14_A16del 
Inframe 
Deletion 
4 / 0  / 1 0%  
(0/848) 
0.05244% 
(2/3814) 
MBP 18q23 rs149668522 
 
c.194C>T 
p.P65L  
Missense 
4 / 0 / 1 0%  
(0/848) 
0.2069% 
(76/36732) 
ZNF816 19q13.41 rs61740548 
 
c.1768G>C 
p.E590Q  
Missense 
3 / 1 / 1 0%  
(0/848) 
0.4302% 
(522/121346) 
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3. Variants that passed filtering criteria, were detected in 4/5 exomes, and were not 
previously reported in dbSNP: 
 
Gene Chr. 
Position 
Variant Details  
 
# Het / # Hom for 
Minor Allele / # 
Hom for Reference 
Allele  
MAF in 
MUGQIC 
Controls 
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
AIM1L 1p36.11 
 
c.28C>G 
p.R10G 
Missense 
4 / 0 / 1 0%  
(0/848) 
0.004735% 
(1/21118) 
C2orf62 2q35 c.222G>C 
p.E65Q  
Missense 
4 / 0 / 1 0%  
(0/848) 
N/A 
ADPRH 3q13.33 c.91G>A 
p.E31K  
Missense 
4 / 0 / 1 0%  
(0/848) 
N/A 
MUC4 3q29 c.7183A>T 
p.T2395S  
Missense 
4 / 0 / 1 0%  
(0/848) 
0.003966% 
(1/25216) 
MUC4 3q29 c.3053C>G 
p.S1018C 
Missense 
4 / 0 / 1 0.12% 
(1/848) 
0.003766% 
(1/26552) 
MGST2 4q31.1 c.44C>T 
p.S15L  
Missense 
4 / 0 / 1 0%  
(0/848) 
N/A 
MCC 5q22.2 c.60_61insTCGGCGGCA 
p.G20_G21insSAA  
Inframe Insertion 
4 / 0 / 1 0%  
(0/848) 
N/A 
LAMA4 6q21 c.1546G>A 
p.V516M 
Missense 
4 / 0 / 1 0%  
(0/848) 
N/A 
TRPA1 8q21.11 c.1309G>A 
p.V437M  
Missense 
4 / 0 / 1 0% 
 (0/848) 
N/A 
CCDC178 18q12.1 c.764C>G 
p.A255G  
Missense 
4 / 0 / 1 0.12% 
(1/848) 
N/A 
KIAA1210 Xq24 c.263C>A 
p.P88Q  
Missense 
1 / 3 / 1 0%  
(0/848) 
0.002018% 
(1/49550) 
 
 
Abbreviations: Het = heterozygous, Hom = homozygous  
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Appendix E: Additional Low Impact Variants in Family R1256 
 
Variants that passed filtering criteria, and were detected in 4/5 exomes:  
 
Gene  Chr. 
Position 
Status in 
dbSNP (rs #) 
Variant 
Details 
# Het / # Hom 
for Minor Allele 
/ # Hom for 
Reference Allele 
MAF in 
MUGQIC 
controls 
(/848) 
MAF in 
ExAC 
Browser 
(/alleles) 
POU3F1 1p34.3 rs201037684 
 
c.1272A>T 
p.A424 
4 / 0 / 1 0.47% 
(4/848) 
0%  
(0/974)  
B3GALNT2 
 
1q42.3 Unreported c.1290G>A 
p.S430 
4 / 0 / 1 0.12%  
(1/848) 
N/A 
FAM110C 2p25.3 rs761388273 c.168G>A 
p.R56 
3 / 1 / 1 0%  
(0/848) 
N/A 
SNRNP200 2q11.2 rs139731897 c.5664C>T 
p.H1888 
4 / 0 / 1 0.71% 
(6/848) 
0.2891% 
(351/121410) 
LONRF2 2q11.2 
 
rs148009215 c.1437C>T 
p.H479 
4 / 0 / 1 0.24% 
(2/848) 
0.1071% 
(130/121412) 
MRPS9 2q12.1 
 
rs149463519 c.711G>A 
p.E237 
4 / 0 / 1 0.24% 
(2/848) 
0.1254% 
(152/121232) 
CHCHD5 2q14.1 
 
rs146873532 c.72G>A 
p.A24 
4 / 0 / 1 0%  
(0/848) 
0.003301% 
(4/121184) 
POTEF 2q21.1 
 
rs201958629 c.2172C>T 
p.D724 
4 / 0 / 1 0.12% 
(1/848) 
0.02214% 
(13/58718) 
LANCL1 2q34 
 
rs147186536 c.843G>A 
p.G281 
4 / 0 / 1 0%  
(0/848) 
0.001664% 
(2/120184) 
IL17RC 3p25.3 
 
rs181990653 c.1716C>G 
p.G572 
4 / 0 / 1 0.35% 
(3/848) 
0.5044% 
(468/92792) 
MUC4 3q29 
 
rs74612617 c.5820T>C 
p.T1940 
4 / 0 / 1 0.59% 
(5/848) 
0.9803% 
(234/23870) 
DDX60L 4q32.3 
 
rs200379104 c.1410G>A 
p.P470 
3 / 1 / 1 0.24%  
(2/848) 
0.006123% 
(6/97984) 
LRRC69 8q21.3 
 
rs138518526 c.738C>T 
p.N246 
4 / 0 / 1 0% 
(0/848) 
0.07696% 
(17/22088) 
UCMA 10p13 
 
Unreported c.204C>T 
p.S68 
4 / 0 / 1 0% 
(0/848) 
N/A 
WDFY4 10q11.23 
 
Unreported c.4068G>A 
p.G1356 
4 / 0 / 1 0.47% 
(4/848) 
N/A 
ZSWIM8 10q22.2 
 
rs201945010 c.1164C>T 
p.S388 
4 / 0 / 1 0% 
(0/848) 
0.0185% 
(22/118912) 
MUC5B 11p15.5 rs75760167 
 
c.3372T>C 
p.C1124 
4 / 0 / 1 0% 
(0/848) 
N/A 
rs74763753 
 
c.3390T>C 
p.A1130 
4 / 0 / 1 0% 
(0/848) 
0.004034% 
(1/24790) 
rs79585387 
 
c.3411C>T 
p.H1137 
 
4 / 0 / 1 0% 
(0/848) 
N/A 
 172 
CTSC 11q14.2 rs181685520 c.-45C>G 
(Start-gained) 
4 / 0 / 1 0.24%  
(2/848) 
0.3819% 
(55/14402) 
SIK2 11q23.1 
 
rs200427353 c.1386C>T 
p.A462 
4 / 0 / 1 0.12% 
(1/848) 
0.02728% 
(33/120976) 
SIK3 11q23.3 
 
rs560511616 c.1629G>A 
p.Q543 
4 / 0 / 1 0.12% 
(1/848) 
0.02797% 
(25/89388) 
PRB4 12p13.2 
 
rs146939904 c.408C>A 
p.G136 
4 / 0 / 1 59% 
(5/848) 
0.3851% 
(464/120478) 
HNRNPA1 12q13.13 
 
rs536130883 c.462C>T 
p.D154 
4 / 0 / 1 0.12% 
(1/848) 
0.006657% 
(8/120182) 
PAPLN 14q24.2 
 
rs145397376 c.2718C>T 
p.D906 
4 / 0 / 1 0.12% 
(1/848) 
0.6774% 
(815/120312) 
MEF2A 15q26.3 
 
rs367780642 c.1071G>A 
p.P357 
4 / 0 / 1 0.47% 
(4/848) 
0.1052% 
(21/19956) 
PKD1L2 16q23.2 
 
Unreported c.45C>T 
p.D15 
4 / 0 / 1 0% 
(0/848) 
N/A 
NLRP1 17p13.2 
 
Unreported c.3510G>A 
p.V1170 
4 / 0 / 1 0% 
(0/848) 
N/A 
MUC16 19p13.2 
 
rs200235837 c.39564C>T 
p.G13188 
4 / 0 / 1 0% 
(0/848) 
N/A 
ZSCAN22 19q13.43 rs756431968 c.162C>T 
p.H54 
4 / 0 / 1 0% 
(0/848) 
N/A 
 
Abbreviations: Het = heterozygous, Hom = homozygous  
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Appendix F: IA-Related Keywords and Abbreviations 
 
 
Phenotype: 
 intracranial aneurysm (ICA; IA) 
 cerebral aneurysm  
 subarachnoid hemorrhage (SAH) 
 cerebral hemorrhage 
 stroke 
 hemorrhagic stroke 
 cerebrovascular disease 
 hypertension 
 Ehlers-Danlos syndrome 
 polycystic kidney disease (PCKD) 
 aortic aneurysm  
 abdominal aortic aneurysm (AAA) 
 
Physiology: 
 artery  
 blood vessel  
 brain  
 blood pressure 
 vascular smooth muscle cells (VSMC) 
 vascular endothelial cells  
 extracellular matrix (ECM) 
 
Pathways & Proteins:  
 inflammation  
 hemodynamic stress  
 vasculature development  
 vascular process in circulatory system  
 endothelin 
 collagen  
 elastin  
 fibrillin  
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Appendix G: Additional Pedigrees for Family R1256 
 
Validated Moderate Impact Variants:  
 
(A) DOPEY1 c.6902C>T 
 
 
 
 
 
(B) KNDC1, c.2686G>T 
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(C) MTG1, c.611C>T 
 
 
 
 
(D) ZPBP2, c.622A>T 
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(E) CCDC3, c.217C>G 
 
 
 
 
Validated High Impact Variants: 
 
(F) OCIAD1, c.-6+1G>A 
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(G) CCDC3, c.425delA 
 
 
 
The symbol +/+ is used to indicate individuals that are heterozygous for the deletion, and -/- is 
used to indicate the absence of the variant.  
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Appendix H: Functional Annotation of Moderate Impact Candidates 
 in Family R1256 
 
 
Gene Variant 
Details 
GERP Polyphen
2 
SIFT Gene Description  
DOPEY1 c.6902C>T; 
p.A2301V 
 
5.77 D 1 Dopey family member 1; may be 
involved in protein transport between 
golgi and endosomes  
KNDC1 c.2686G>T; 
p.A896S 
 
3.83 D 0.06 Kinase non-catalytic C-lobe domain 
containing 1; is a guanine nucleotide 
exchange factor, has high expression in 
the brain 
MTG1 c.611C>T; 
p.P204L 
 
5.59 D 0 Mitochondrial ribosome-associated 
GTPase 1; involved in GTP binding, 
which is involved in signal transduction 
processes 
ZPBP2 c.622A>T; 
p.T208S 
 
5.67 B 0.35 Zona pellucida-binding protein 2; has 
expression in testis and brain medulla 
CCDC3 c.217C>G; 
p.L73V 
 
4.33 D 0.06 Coiled-coil domain containing 3; 
expressed in adipose tissue and 
endothelial cells  
 
GERP scores above 3.00 are considered to be predictive of evolutionary conservation. For 
Polyphen2 scores, D=damaging, and B=benign. For SIFT scores, values below or equal to 0.05 
are considered to be damaging, while values from 0.05 to 1 are benign or “tolerated” changes. 
Gene functions and pathway annotations are collected from UniProt, OMIM, DAVID and 
GeneCards.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
